

# BAKER BOTTS LLP

30 ROCKEFELLER PLAZA  
44TH FLOOR  
NEW YORK, NEW YORK  
10112-4498  
212.705.5000  
FAX 212.705.5020

AUSTIN  
BAKU  
DALLAS  
HOUSTON  
LONDON  
MOSCOW  
NEW YORK  
WASHINGTON

Appln. Trans.  
PATENT

## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional  
applications under 37 CFR 1.53(b))

Attorney Docket No. A31488-II 065360.0142

First Named Inventor Rothman et al.

Express Mail Label No. EK839861833US

Total Pages 100

jc925 U.S. PRO  
09/696872  
10/26/00

October 26, 2000

**BY EXPRESS MAIL - Label No. EK839861833US**

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

Sir:

Enclosed herewith for filing is a patent application of Rothman et al. entitled KDEL RECEPTOR  
INHIBITORS

which includes:

<input checked="" type="checkbox"/> Specification	<u>27</u> Total Pages
<input checked="" type="checkbox"/> Claims	<u>4</u> Total Pages
<input checked="" type="checkbox"/> Abstract	<u>1</u> Total Pages
<input checked="" type="checkbox"/> Drawing(s)	<u>    </u> Total Sheets
<input checked="" type="checkbox"/> formal	<u>30</u> Total Sheets
<input checked="" type="checkbox"/> informal	<u>30</u> Total Sheets

☒ Combined Declaration and Power of Attorney 8 Total Pages

☐ Newly executed (original or copy)

☒ Copies from a prior application

(for continuation/divisional only - must be filed to avoid surcharge for late filing)

If a continuing application, check appropriate box:

☐ Continuation ☒ Divisional  
of prior application No. 09/124,671

☐ Continuation-In-Part (CIP)

☒ Amend the specification by inserting, before the first line, the following sentence:

"This is a ☐ continuation ☒ divisional ☐ continuation-in-part  
of copending application Serial No. 09/124,671 filed July 29, 1998."

Attorney Docket No. A31488-II 065360.0142

- ☒ An Assignment of the invention to SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH.  
☐ is attached. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.  
☐ will follow.  
☒ has been filed in the prior application

- ☐ Small Entity Statement(s) **ENCLOSED**.  
☒ Small Entity Statement filed in prior application. Status still proper and desired.

- ☐ Information Disclosure Statement (IDS) PTO-1449  
☐ Copies of IDS Citations.

☒ Preliminary Amendment (with hard copy of Sequence Listing and a soft copy in a diskette)

☒ Return Receipt Postcard

☒ Other : Check for \$355.00

☒ Cancel in this application original claims 1-19 and 38-43 of the prior application before calculating the filing fee.

The filing fee has been calculated as shown below:

FOR	(Col. 1) No. Filed	(Col. 2) No. Extra	Small Entity Rate	Fee	OR	Other Than A Small Entity Rate	Fee
Basic Fee							
Total Claims	18	-20 = 0	x 9 =	\$0.00	x 18 =	\$0.00	
Ind. Claims	<u>1</u>	-3 = 0	x 40 =	\$0.00	x 80 =	\$0.00	
Multiple Dependent Claim			+ 135 =		+ 270 =		
			Total	<u>\$0.00</u>			<u>\$0.00</u>

\* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

Fee Payment Being Made:

☒ Enclosed

☒ Basic filing fee \$355.00

☐ Recording Assignment \$0.00  
 [\$40.00; 37 CFR 1.21(h)]

Total Fees Enclosed \$355.00

Appln. Trans.  
PATENT

Attorney Docket No. A31488-II 065360.0142

☒ A check in the amount of \$355.00 to cover filing fee is enclosed.

Priority

☐ Priority of application Country \_\_, Appln. No. \_\_ filed \_\_ is claimed under 35 U.S.C. 119.

☐ Certified Copy of Priority Document(s) Country \_\_, Appln No. \_\_, filed \_\_.

☐ is/are attached ☐ will follow ☐ has been filed in the parent application S/N \_\_.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR 1.16, 1.17, and 1.21(h) associated with this communication or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

BAKER BOTTS L.L.P.



By : Richard S. Clark  
PTO Registration No. 26,154

Lisa B. Kole  
PTO Registration No. 35,225

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Rothman, et al.

Serial No. : divisional of 09/124,671 Examiner: to be assigned, formerly  
Tung, P.


Filed : herewith Group Art Unit: to be assigned  
formerly 1652

For : KDEL RECEPTOR INHIBITORS

PRELIMINARY AMENDMENT

I hereby certify that this paper is being deposited with the United States Postal  
Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231

October 26, 2000  
Date of Deposit

Lisa B. Kole  
Attorney Name  
  
Signature

35,225  
PTO Registration No.

October 26, 2000  
Date of Signature

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the examination of the above-identified patent application, please enter  
the following amendments.

AMENDMENTSIN THE SPECIFICATION:

Please amend the specification as follows:

At page 2, line 22, after “herein as KDEL”, please insert - -(SEQ ID NO:37)- - .

At page 2, line 25, please replace “KDEL-containing ligand” with - - KDEL (SEQ ID NO:37)-containing ligand - - .

At page 3, line 22, please replace “KDEL-mediated” with - - KDEL (SEQ ID NO:37)-mediated - - .

At page 6, line 6, please replace “KDEL. Restriction” with - - KDEL (SEQ ID NO:37). Restriction - - .

At page 6, line 9, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 6, line 13, please replace “sub-sequence GDLA (from” with - - sub-sequence GDLA (SEQ ID NO:40; from - - .

At page 6, line 14, please replace “linked to KDEL.” with - - linked to KDEL (SEQ ID NO:37). - - .

At page 6, line 19, please replace “carboxy-terminal sequence KDEL. ” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 6, line 23, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 6, line 27, please replace “sub-sequence GDCC (an alteration ” with - - sub-sequence GDCC(SEQ ID NO:41; an alteration - - .

At page 6, line 29, please replace “linked to KDEL.” with - - linked to KDEL (SEQ ID NO:37). - - .

At page 7, line 5, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 7, line 9, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 7, line 12, please replace “sub-sequence GDCC (an ” with - - sub-sequence GDCC(SEQ ID NO:41; an - - .

At page 7, line 21, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 7, line 25, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 7, line 28 , please replace “sub-sequence GDCC (an ” with - - sub-sequence GDCC(SEQ ID NO:41; an - - .

At page 8, line 2, please replace “sub-sequence GEQT” with - - sub-sequence GEQT (SEQ ID NO:42) - - .

At page 8, line 3, please replace “and KDEL.” with - - and KDEL (SEQ ID NO:37) - - .

At page 8, line 9, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 8, line 13, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 8, line 16, please replace “the sub-sequence GDCC” with - - the sub-sequence GDCC (SEQ ID NO:41) - - .

At page 8, line 25, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 8, line 28, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 9, line 3, please replace “the sub-sequence GDCC” with - - the sub-sequence GDCC (SEQ ID NO:41) - - .

At page 9, line 4, please replace “and KDEL.” with - - and KDEL (SEQ ID NO:37). - - .

At page 9, line 10, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 9, line 14, please replace “amino acids KDEL” with - - amino acids

KDEL (SEQ ID NO:37) - - .

At page 9, line 17, please replace “the sub-sequence GDCC” with - - the sub-sequence GDCC (SEQ ID NO:41) - - .

At page 9, line 19, please replace “and KDEL.” with - - and KDEL (SEQ ID NO:37). - - .

At page 9, line 25, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 9, line 29, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 10, line 3, please replace “the sub-sequence GDCC” with - - the sub-sequence GDCC (SEQ ID NO:41) - - .

At page 10, line 5, please replace “and KDEL.” with - - and KDEL (SEQ ID NO:37). - - .

At page 10, line 10, please replace “carboxy-terminal sequence KDEL.” with - - carboxy-terminal sequence KDEL (SEQ ID NO:37). - - .

At page 10, line 14, please replace “amino acids KDEL” with - - amino acids KDEL (SEQ ID NO:37) - - .

At page 10, line 17, please replace “the sub-sequence GDCC” with - - the sub-sequence GDCC (SEQ ID NO:41) - - .

At page 10, line 19, please replace “and KDEL.” with - - and KDEL (SEQ ID NO:37). - - .

At page 10, line 25, please replace “KDEL. (B)” with - - KDEL (SEQ ID NO:37). (B) - - .

At page 10, line 27, please replace “the sub-sequence GDCC” with - - the sub-sequence GDCC (SEQ ID NO:41) - - .

At page 10, line 29, please replace “KDEL. (C-D)” with - - KDEL (SEQ ID NO:37). (C-D) - - .

At page 11, line 16, please replace “carboxy-terminal KDEL sequence” with - - carboxy-terminal KDEL sequence (SEQ ID NO:37) - - .

At page 11, line 25, please replace “(“XDEL”)” with - - (“XDEL”; SEQ ID NO:38) - - .

At page 11, line 27, please replace “(KDEL)” with - - (SEQ ID NO:38) - - .

At page 12, line 2, please replace “(SEKDEL)” with - - (SEKDEL; SEQ ID NO:39) - - .

At page 12, line 3, please replace “(KDEL)” with - - (KDEL; SEQ ID NO:37) - - .

At page 12, line 28, please replace “XDEL” with - - XDEL (SEQ ID NO:38) - - .

At page 13, line 1, please insert, after “Glu Leu”, - - (SEQ ID NO:37) - - .

At page 17, line 4, please replace “preceding KDEL.” with - - preceding KDEL (SEQ ID NO:37) . - - .

At page 17, line 7, please replace “sequence KDEL.” with - - sequence KDEL (SEQ ID NO:37). - - .

At page 17, line 11, please replace “terminal KDEL sequence.” with - - terminal KDEL sequence (SEQ ID NO:37). - - .

At page 17, line 17, please replace “sequence KDEL.” with - - sequence KDEL (SEQ ID NO:37). - - .

At page 17, line 20, please replace “C-terminal KDEL sequence.” with - - C-terminal KDEL sequence. - - .

At page 17, line 26, please replace “KDEL. FIGURE 6A” with - - KDEL (SEQ ID NO:37). FIGURE 6A - - .

At page 17, line 29, please replace “terminal KDEL sequence.” with - - terminal KDEL sequence (SEQ ID NO:37). - - .

At page 22, line 19, please replace “KDEL-bearing” with - - KDEL (SEQ ID NO:37) - bearing - - .

At page 26, line 10, please replace “KDEL-containing” with - - KDEL (SEQ ID NO:37)-containing - - .

Please replace the existing Sequence Listing with the replacement Sequence Listing submitted herewith.



IN THE CLAIMS:

Please amend the claims as follows:

Please cancel claims 1-19 and 38-43.

REMARKS

Claims 20-37 are pending. Claims 1-19 and 38-43 are cancelled without prejudice to their prosecution in other patent applications.

The specification has been amended to conform with the rules regarding Sequence Listings. A new Sequence Listing is submitted herewith in paper and computer readable form. Applicants assert that the paper and computer readable forms of the Sequence Listing are the same and contain no new matter.

Respectfully submitted,



Richard S. Clark

Patent Office Reg. No. 26,154

Lisa B. Kole

Patent Office Reg. No. 35, 225

Attorneys for Applicants

(212) 408-2500

BAKER & BOTTS  
30 ROCKEFELLER PLAZA  
NEW YORK, NEW YORK 10112

TO ALL WHOM IT MAY CONCERN:

Be it known that WE, James E. Rothman, Mark Mayhew , and Mee H. Hoe, citizens of the United States, Great Britain, and Malaysia, respectively; residing in the County of New York, State of New York; the County of Westchester, State of New York; and the County of New York, State of New York, respectively; whose post office addresses are 402 E. 64<sup>th</sup> Street, Apt. 10B, New York, New York 10021, 414 Benedict Avenue, Apt. 3E, Tarrytown, New York 10591, and 312 E. 66<sup>th</sup> Street, Apt. 4C, New York, New York 10021, respectively, have invented an improvement in

KDEL RECEPTOR INHIBITORS

of which the following is a

SPECIFICATION

1. INTRODUCTION

The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence at the protein carboxy terminus and a KDEL-binding receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.

## 2. BACKGROUND OF THE INVENTION

A living cell is a complex assembly of molecular elements; to function properly, its constituent molecules must form associations and operate in an organized manner. Certain components bind together to form molecular superstructures, including organelles which compartmentalize cellular activities and filaments which impart order and control motility. Other components exist in soluble form, and may move freely throughout the cell or, alternatively, within a subcellular compartment.

Cells are also equipped with elements that synthesize, process, and secrete a designated subset of proteins. This so-called secretory pathway includes membrane associated structures, such as the endoplasmic reticulum and Golgi apparatus, as well as a number of resident soluble molecules which participate in the processing of secreted proteins. Proteins which are to be secreted pass through the Golgi apparatus, where they are packaged for export from the cell. Accompanying them, by virtue of the continual vesicular transport of membrane and endoplasmic reticulum luminal contents, are soluble proteins properly residing in the endoplasmic reticulum.

To avoid continuously losing and needing to resynthesize these resident proteins, the cell uses a membrane-bound receptor localized in or near the Golgi apparatus for their retrieval (Lewis and Pelham, 1992, Cell 68:353-364). The receptor binds to a specific carboxy-terminal amino acid sequence which serves as a marker of what proteins are to be returned to the endoplasmic reticulum; this sequence is generally lysine-aspartic acid-glutamic acid-leucine (Lys-Asp-Glu-Leu in the three-letter amino acid code, KDEL in the single-letter code, referred to herein as "KDEL"), so that the receptor is generally referred to as the KDEL receptor (Munro and Pelham, 1987, Cell 48:899-907; Pelham, 1988, EMBO J. 7:913-918). The human KDEL receptor has been characterized as a seven-transmembrane domain protein which is a temporary resident of the Golgi apparatus: upon binding to a KDEL-containing ligand, it moves to the endoplasmic reticulum, where the ligand is released (Townesley et al., 1993, EMBO J. 12:2821-2829).

Among the molecules interacting with the KDEL receptor are certain members of a class of proteins, referred to as "heat shock proteins", which form associations with nascent

polypeptides in the endoplasmic reticulum and act as molecular "chaperones", escorting a protein through the assembly process prior to its secretion (Frydman et al., 1994, *Nature* 370:111-117; Hendrick and Hartl, *Annu. Rev. Biochem.* 62:349-384; Hartl, 1996, *Nature* 381:571-580). Heat shock proteins constitute a highly conserved class of proteins selectively expressed in cells under stressful conditions, such as sudden increases in temperature or glucose deprivation. Able to bind to a wide variety of other proteins in their non-native state, heat shock proteins participate in the manufacture of these bound proteins, including their synthesis, folding, assembly, disassembly and translocation (Freeman and Morimoto, 1996, *EMBO J.* 15:2969-2979; Lindquist and Craig, 1988, *Annu. Rev. Genet.* 22:631-677; Hendrick and Hartl, 1993, *Annu. Rev. Biochem.* 62:349-384).

Two heat shock proteins which contain ligand sequences for the KDEL receptor are gp96 and BiP. Found in higher eukaryotes but not in *Drosophila* or yeast, gp96 appears to have evolved relatively recently, perhaps by a duplication of the gene encoding the cytosolic heat shock protein hsp90, to which it is highly related (Li and Srivastava, 1993, *EMBO J.* 12:3143-3151; identity between human hsp90 and murine gp96 is about 48 percent; Wiech et al., 1992, *Nature* 358:169-170; Melnick et al., 1992, *J. Biol. Chem.* 267:21303-21306; Melnick et al., 1994, *Nature* 370:373-375; Schaiff et al., 1992, *J. Exp. Med.* 176:657-666; Ramakrishnan et al., 1995, *DNA and Cell Biol.* 14:373-384). BiP (also referred to in the literature as grp78) forms a complex with newly synthesized immunoglobulin chains (Bole et al., 1986, *J. Cell Biol.* 102:1558-1566).

Under certain circumstances, it may be desirable to interfere with the normal control of KDEL-mediated protein redistribution. According to the present invention, a subject may benefit, for example, from the secretion of heat shock proteins which are normally retained in the endoplasmic reticulum but which have beneficial immunogenic effects when released.

Heat shock proteins are believed to play a role in the immune response in several contexts. Inoculation with heat shock protein prepared from tumors of experimental animals has been shown to induce immune responses in a tumor-specific manner; that is to say, heat shock protein gp96 purified from a particular tumor could induce an immune response which would inhibit the growth of cells from the identical tumor of origin, but not other tumors, regardless of

relatedness (Srivastava and Maki, 1991, Curr. Topics Microbiol. 167:109-123). High-resolution gel electrophoresis has indicated that tumor-derived gp96 may be heterogeneous at the molecular level; evidence suggests that the source of this heterogeneity may be populations of small peptides adherent to the heat shock protein, which may number in the hundreds (Feldweg and Srivastava, 1995, Int. J. Cancer 63:310-314). Indeed, an antigenic peptide of vesicular stomatitis virus has been shown to associate with gp96 in virus infected cells (Niemand et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:6135-6139). It has been suggested that this accumulation of peptides is related to the localization of gp96 in the endoplasmic reticulum, where it may act as a peptide acceptor and accessory to peptide loading of major histocompatibility complex class I molecules (Li and Srivastava, 1993, EMBO J. 12:3143-3151; Suto and Srivastava, 1995, Science 269:1585-1588). Recent studies have shown that protein disulfide isomerase ("PDI"), a resident luminal protein of the endoplasmic reticulum having a molecular weight of approximately 60kDa, may also function as a peptide acceptor (Lammert et al., 1997, Eur. J. Immunol. 27:1685-1690).

Further, the use of heat shock proteins as adjuvants to stimulate an immune response has been proposed (see, for example, Edgington, 1995, Bio/Technol. 13:1442-1444; PCT Application International Publication Number WO 94/29459 by the Whitehead Institute for Biomedical Research, Richard Young, inventor, and references *infra*). One of the best known adjuvants, Freund's complete adjuvant, contains a mixture of heat shock proteins derived from mycobacteria (the genus of the bacterium which causes tuberculosis); Freund's complete adjuvant has been used for years to boost the immune response to non-mycobacterial antigens. A number of references suggest, *inter alia*, the use of isolated mycobacterial heat shock proteins for a similar purpose, including vaccination against tuberculosis itself (Lukacs et al., 1993, J. Exp. Med. 178:343-348; Lowrie et al., 1994, Vaccine 12:1537-1540; Silva and Lowrie, 1994, Immunology 82:244-248; Lowrie et al., 1995, J. Cell. Biochem. Suppl. 0(19b):220; Retzlaff et al., 1994, Infect. Immun. 62:5689-5693; PCT Application International Publication No. WO 94/11513 by the Medical Research Council, Colston et al., inventors; PCT Application International Publication No. WO 93/1771 by Biocine Sclavo Spa, Rappuoli et al., inventors).

Increased levels of autologous heat shock proteins may also lead to an improved immune response by virtue of the association of heat shock proteins with endogenous antigenic

peptides (International Application No. PCT/US96/13233 by Rothman et al.). Such activity is distinct from the traditionally utilized adjuvant activity of heterologous heat shock proteins.

The present invention is directed toward increasing the secretion of antigenic heat shock protein complexes by inhibiting KDEL receptor-mediated return of such complexes to the endoplasmic reticulum. Analogous methods may be used to increase the secretion of other proteins of interest which normally would tend to be retained via the KDEL receptor.

### 3. SUMMARY OF THE INVENTION

The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. It is based, at least in part, on the ability of such inhibitors to promote the secretion of proteins which would otherwise tend to be retained in the cell in which they are produced.

In nonlimiting embodiments, the present invention provides for a protein comprising a plurality of amino acid sequences which bind to the KDEL receptor. Such an inhibitory protein, introduced into a cell, would promote the secretion of proteins which would otherwise tend to be functionally retained in the cell via interaction with the KDEL receptor. The secreted proteins may include proteins naturally produced by the cell and/or proteins expressed as a result of the introduction of nucleic acid encoding said proteins into the cell or a progenitor thereof. As specific, nonlimiting examples, the secretion of certain endogenous or exogenously introduced heat shock proteins may be promoted in this manner. Moreover, the KDEL receptor inhibitor protein may be introduced into a cell in conjunction with an antigenic peptide capable of associating with a heat shock protein, and used to promote the secretion of heat shock protein/antigenic peptide complexes.

In further embodiments, the present invention provides for the identification of further compounds, including peptomimetic compounds, which inhibit the association of a KDEL receptor with its protein ligands which may, for example, be prepared by combinatorial chemistry techniques or identified by phage display. Such compounds may be used in methods analogous to those described above to promote the secretion of certain proteins.

#### 4. DESCRIPTION OF THE FIGURES

FIGURE 1. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (in this example, from mouse BiP); (ii) the oligomerization domain of rat cartilage oligomeric matrix protein (COMP); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein encoded by the construct depicted in (A) (SEQ ID NO:13), showing the cleavable leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDLA (from the rat COMP), the rat COMP pentamerization domain (overlined), and the camel IgG linker domain (underlined and overlined), linked to KDEL. (C-D) Nucleic acid sequence of the rat COMP-KDEL construct shown in (A) (SEQ ID NO:14).

FIGURE 2.(A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of rat cartilage oligomeric matrix protein (COMP); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein encoded by the construct depicted in (A) (SEQ ID NO:15), showing the cleavable leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC (an alteration of the rat COMP sub-sequence shown in FIGURE 1B which provides increased stability via disulfide bonds); the rat COMP pentamerization domain (overlined), and the camel IgG linker domain (underlined and overlined), linked to KDEL. (C-

D) Nucleic acid sequence of the rat COMP-KDEL construct shown in (A) (SEQ ID NO:16).

FIGURE 3. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of mouse thrombospondin 3 trimerization domain (TSP3); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:17), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC (an alteration of the rat COMP sub-sequence shown in FIGURE 1B which provides increased stability via disulfide bonds), the mouse TSP3 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the mouse TSP3-KDEL construct shown in (A) (SEQ ID NO:18), indicating the translation start site (circled) and termination site (boxed).

FIGURE 4. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of mouse thrombospondin 3 trimerization domain (TSP3); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:19), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC (an alteration of the rat COMP sub-sequence shown in FIGURE 1B which provides increased



stability via disulfide bonds), the mouse TSP3 trimerization domain (overlined, including an additional sub-sequence GEQT at the 5' end relative to FIGURE 3B), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the mouse TSP3-KDEL construct shown in (A) (SEQ ID NO:20), indicating the translation start site (circled) and termination site (boxed).

FIGURE 5. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from mouse BiP); (ii) the oligomerization domain of *Xenopus* thrombospondin 4 trimerization domain (TSP4); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:21), indicating the leader/signal peptide (underlined) plus linker (represented by the amino acids -GSS-), the sub-sequence GDCC, the *Xenopus* TSP4 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the *Xenopus* TSP4-KDEL construct shown in (A) (SEQ ID NO:22), indicating the translation start site (circled) and termination site (boxed).

FIGURE 6. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (in this example from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human cartilage oligomeric matrix protein (COMP); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL. Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid

sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:23), indicating the leader/signal peptide (underlined) plus linker (represented by the amino acids -GSS-), the sub-sequence GDCC, the human COMP pentamerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human COMP-KDEL construct shown in (A) (SEQ ID NO:24), indicating the translation start site (circled) and termination site (boxed).

FIGURE 7. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human phospholamban (PLB); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL.

Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a

peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:25), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC, the human PLB pentamerization domain (overlined, residues critical for pentamer formation marked by a dot), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human PLB-KDEL construct shown in (A) (SEQ ID NO:26), indicating the translation start site (circled) and termination site (boxed).

FIGURE 8. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human thrombospondin 3 (TSP3); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL.

Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a

peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:27), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC, the human TSP3 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human TSP3-KDEL construct shown in (A) (SEQ ID NO:28), indicating the translation start site (circled) and termination site (boxed).

FIGURE 9. (A) Schematic representation of a nucleic acid molecule encoding a KDEL receptor inhibitor protein comprising regions encoding (i) a cleavable signal peptide (from adenovirus E3/19 kDa protein); (ii) the oligomerization domain of human thrombospondin 4 (TSP4); (iii) a camel IgG linker domain; and (iii) the carboxy-terminal sequence KDEL.

Restriction endonuclease cleavage sites which may be used to incorporate the coding sequences into a number of vectors, known in the art, are shown. A double asterisk (\*\*) denotes a Bam HI site located 3' to the signal peptide encoding sequence or a Kpn I site at the 5' end preceding the nucleotides encoding the amino acids KDEL into which, for example, nucleic acid encoding a peptide/target antigen may be inserted. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:29), indicating the leader/signal peptide (underlined) plus linker (represented by amino acids -GSS-), the sub-sequence GDCC, the human TSP4 trimerization domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the human TSP4-KDEL construct shown in (A) (SEQ ID NO:30), indicating the translation start site (circled) and termination site (boxed).

FIGURE 10. (A) Schematic representation of a nucleic acid molecule encoding a KDEL inhibitor protein having (i) a cleavable signal peptide from mouse BiP; (ii) a myc-tag; (iii) an N-linked glycosylation sequence; (iv) the oligomerization domain of the rat cartilage oligomerization protein; (iv) a camel IgG linker domain; and (v) the carboxy terminal sequence KDEL. (B) Amino acid sequence (single letter code) of KDEL receptor inhibitor protein shown in (A) (SEQ ID NO:34), indicating the leader/signal peptide (underlined), myc-tag, N-linked glycosylation sequence, linker (represented by amino acids -GSS-), the sub-sequence GDCC, the rat COMP domain (overlined), the camel IgG linker domain (overlined and underlined) and KDEL. (C-D) Nucleic acid sequence of the KDEL construct shown in (A) (SEQ ID NO:35),

indicating the translation start site (circled) and termination site (boxed).

## 5. DETAILED DESCRIPTION OF THE INVENTION

For purposes of clarity of presentation and not by way of limitation, the detailed description of the invention is divided into the following subsections:

- (i) KDEL receptor inhibitor proteins; and
- (ii) uses of KDEL receptor inhibitors.

### 5.1. KDEL RECEPTOR INHIBITOR PROTEINS

The present invention provides for a protein comprising a plurality of amino acid sequences which bind to a KDEL receptor (hereafter referred to as a "KDELr inhibitor protein"). By containing a plurality of such sequences, said protein may favorably compete with naturally occurring proteins which bind to the KDEL receptor but which contain a single binding sequence. In preferred, nonlimiting embodiments, the KDELr inhibitor protein is oligomeric, comprising a plurality of subunit proteins each of which comprise, at their carboxy terminal end, a sequence which binds to a KDEL receptor.

The term "KDEL receptor", as used herein, refers to a protein which selectively and specifically binds to a carboxy-terminal KDEL sequence in proteins, and which participates in the redistribution of bound proteins from the Golgi complex to the endoplasmic reticulum. In specific, nonlimiting embodiments, KDEL receptors include the protein encoded by ERD2 in *Saccharomyces cerevesiae* ("ERD2") as well as its human homolog ("hERD2"), as well as structurally and functionally homologous proteins, such as ELP-1, which is 83 percent identical to human ERD-2 (Lewis et al., 1990, Nature 348:162-162; Semenza et al., 1990, Cell 61:1349-1357; Lewis and Pelham, 1992, J. Mol. Biol. 226:913-916; Lewis and Pelham, 1992, Cell 68:353-364; Hsu et al., 1992, Cell 69:625-635).

In specific, nonlimiting embodiments, the amino acid sequence which binds to the KDEL receptor is X-Asp Glu Leu ("XDEL"), where X may be any amino acid, preferably lysine or histidine and most preferably lysine, and is located at the carboxy terminus such that the ultimate C-terminal residue is the leucine of X-Asp-Glu-Leu (KDEL). In specific nonlimiting

embodiments of the invention, the carboxy terminal sequence may be Ser-Glu-Lys-Asp-Glu-Leu ("SEKDEL"). Additional amino acid sequences which may bind to the KDEL receptor may be identified by testing the ability of such sequences to compete with Lys-Asp-Glu-Leu (KDEL) for binding to the KDEL receptor in a cell (see, for example, experiments described in Munro and Pelham, 1987, Cell 48:899-907) or under comparable conditions *in vitro*.

Where the KDELr inhibitor protein is oligomeric, it may comprise a plurality of subunits, wherein the subunits may be structurally the same (*i.e.*, a "homooligomer") or different (*i.e.*, a "heterooligomer"). Each subunit may comprise a carboxy terminus which binds to a KDEL receptor, and the remainder of the subunit, or a portion thereof, may permit a means for the association between subunits and the formation of the oligomer. Subunits may be covalently or noncovalently joined together. Where subunits are covalently joined, linkages may result from disulfide bonds, oxidized carbohydrate residues, or crosslinking agents, to name a few nonlimiting examples.

In preferred embodiments of the invention, an amino acid sequence which binds to the KDEL receptor may be incorporated as the carboxy terminus in a protein subunit of an oligomeric protein or portion thereof. Suitable known oligomers may include immunoglobulin molecules; especially preferred, however, are smaller oligomeric molecules, including, but not limited to, pentamers formed via the oligomerization domain of a cartilage oligomeric matrix protein ("COMP", which has been used to produce a high avidity binding protein termed a "peptabody", described in Terskikh et al., 1997, Proc. Natl. Acad. Sci. U.S.A. 94:1663-1668).

Thus, in specific, nonlimiting examples, the present invention provides for a KDELr inhibitor protein formed via association between a plurality of subunits, each comprising the oligomerization domain of a COMP or a homologous oligomeric protein such as thrombospondin 3 ("TSP3", which is trimeric), thrombospondin 4 ("TSP 4", which is trimeric) or phospholamban ("PLB", which is pentameric). As such, the present invention provides for an oligomeric KDELr inhibitor protein comprising a plurality of subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor, for example, a region having, at its carboxy terminus, the XDEL amino acid sequence referred to above. In preferred nonlimiting embodiments of the invention, the region

which binds to a KDEL receptor has the amino acid sequence Lys Asp Glu Leu, and the oligomerization domain has an amino acid sequence selected from the following amino acid sequences (Malashkevick et al., 1996, Science 274:761-765), or a subfragment or homolog thereof which forms an oligomer under conditions as set forth in Efimov et al., 1994, FEBS Letts 341:54-58 and Efimov et al., 1996, Proteins 24:259.

(1) COMP (rat, res. 27-72) Gly-Asp-Leu-Ala-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Glu-Leu-Leu-Arg-Gln-Gln-Val-Lys-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO: 1);

(2) COMP (human) Ser-Asp-Leu-Gly-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Asp-Trp-Leu-Arg-Gln-Gln-Val-Arg-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO:2);

(3) TSP3 (mouse) Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:3);

(4) TSP3 (human) Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:4);

(5) TSP4 (human) Gly-Asp-Phe-Asn-Arg-Gln-Phe-Leu-Gly-Gln-Met-Thr-Gln-Leu-Asn-Gln-Leu-Leu-Gly-Glu-Val-Lys-Asp-Leu-Leu-Arg-Gln-Gln-Val-Lys-Glu-Thr-Ser-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:5);

(6) TSP4 (*Xenopus*) Gly-Asp-Val-Ser-Arg-Gln-Leu-Ile-Gly-Gln-Ile-Thr-Gln-Met-Asn-Gln-Met-Leu-Gly-Glu-Leu-Arg-Asp-Val-Met-Arg-Gln-Gln-Val-Lys-Glu-Thr-Met-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:6); and

(7) PLB (human, residues 26-52) Gln-Lys-Leu-Gln-Asn-Leu-Phe-Ile-Asn-Phe-Cys-Leu-Ile-Leu-Ile-Cys-Leu-Leu-Leu-Ile-Cys-Ile-Ile-Val-Met-Leu-Leu (SEQ ID NO:7).

The foregoing sequences may, for example, be altered by deletion, insertion, or substitution, provided that they remain capable of forming an oligomer under comparable conditions.

KDELr inhibitor proteins may be prepared by any method known in the art, using

either chemical synthesis or genetic engineering techniques. Accordingly, the present invention provides for nucleic acids comprising regions encoding a KDELr inhibitor protein of the invention or a subunit thereof, operably linked to suitable elements which facilitate the expression of the protein, and comprised in a nucleic acid vector. Suitable vectors include, but are not limited to, herpes simplex viral based vectors such as pHSV1 (Geller et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:8950-8954); retroviral vectors such as MFG (Jaffee et al., 1993, Cancer Res. 53:2221-2226), and in particular Moloney retroviral vectors such as LN, LNSX, LNCX, LXSX (Miller and Rosman, 1989, Biotechniques 7:980-989) and semliki forest virus ("SFV") vectors; vaccinia viral vectors such as MVA (Sutter and Moss, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10847-10851); adenovirus vectors such as pJM17 (Ali et al., 1994, Gene Therapy 1:367-384; Berker, 1988, Biotechniques 6:616-624; Wand and Finer, 1996, Nature Medicine 2:714-716); adeno-associated virus vectors such as AAV/neo (Mura-Cacho et al., 1992, J. Immunother. 11:231-237); lentivirus vectors (Zufferey et al., 1997, Nature Biotechnology 15:871-875; pET 11a, pET3a, pET11d, pET3d, pET22d, and pET12a (Novagen); plasmid AH5 (which contains the SV40 origin and the adenovirus major late promoter); pRC/CMV (InVitrogen, Carlsbad, CA); pCMU II (Paabo et al., 1986, EMBO J. 5:1921-1927); pZipNeo SV (Cepko et al., 1984, Cell 37:1053-1062); pSR $\alpha$  (DNAX, Palo Alto, CA); pBK-CMV (Stratagene, La Jolla, CA); pCDNA3 (InVitrogen, Carlsbad, CA); and pCDNA1 (InVitrogen, Carlsbad, CA). Where the KDELr inhibitor protein is oligomeric, oligomers may be formed *in vivo* or *in vitro*. An example of conditions which would produce such oligomers *in vitro* would be a room temperature solution including oxidized and reduced glutathione at concentrations of 10 mM and 2 mM, respectively (Efimov et al., 1994, FEBS Let. 341:54-58).

Any of the KDELr inhibitor proteins described above may be introduced into a cell, wherein the cell is synthesizing, has synthesized, or will synthesize a protein which would tend to bind to a KDEL receptor and hence be returned to the endoplasmic reticulum (hereafter referred to as an "ER protein"), where it is desired that the KDEL receptor inhibitory protein promote the secretion of the ER protein. A KDELr inhibitor protein may be introduced into the cell by any means known in the art, including the introduction of a gene encoding the KDELr inhibitor protein or microvesicles comprising KDELr inhibitor protein.

Where the KDELr inhibitor protein is genetically introduced, a nucleic acid encoding said KDELr inhibitor protein should also encode a signal sequence linked to said protein which targets the KDELr inhibitor protein to the endoplasmic reticulum. Nonlimiting examples of signal sequences which may be used include the mouse BiP signal peptide shown in FIGURES 1-5, the adenovirus E3/19kd signal peptide (Anderson et al., 1991, J. Exp. Med. 174:489-492) as shown in FIGURES 6-9, the human pre-prolactin signal peptide or the human pre-proinsulin signal peptide.

Where the KDELr inhibitor itself is to be introduced into a cell, it may be linked to one or more sugar residue to facilitate its uptake into endosomes, for example, via the insulin receptor (Krupp and Lane, 1982, J. Biol. Chem. 257:1372-1377), the mannose 6 phosphate receptor or the asialoglycoprotein receptor (Berg et al., 1982, Exp. Cell Res. 148:319-330) and Wu, 1988, Biochem. 27:887-892; Plank et al., 1992, Bioconjugate Chem. 3:533-539), or linked to another biological molecule, such as folate (for uptake via the folate receptor; Wang et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92:3318), insulin (for uptake via the insulin receptor; Hockett et al., 1990, Biochem. Pharmacol. 40:253) or transferrin (for uptake via the transferrin receptor; Kuhn et al., 1984, Cell 37:95-103; McClelland et al., 1984, Cell 39:267-274; Morgan et al., 1978, Blood 52:1219-1228; Karin and Mintz, 1981, J. Biol. Chem. 256:3245-3252; Octave et al., 1983, Trends Biochem. Sci. ("TIBS") 8:217-220; Newman et al., 1982, TIBS 7:397-400; Zenke et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:3655). As a nonlimiting specific example, FIGURE 10 depicts a KDEL inhibitor protein comprising an N-linked glycosylation site. The consensus site for N-glycosylation is NXT or NXS. The sequence NST, comprised in the protein depicted in FIGURE 10, is used as an optimized sequence for glycosylation in a context related to KDEL peptide (Misenbock and Rothman, 1995, J. Cell Biol. 129:309-319; see also Kim et al., 1998, Proc. Natl. Acad. Sci. U.S.A. 95:2997-3002). The molecule depicted in FIGURE 10 also comprises a myc-tag sequence (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu; SEQ ID NO: 36), which may be used as a marker for localization of the protein using, for example, monoclonal antibody 9E10.

Where nucleic acid encoding the KDELr inhibitor protein is to be introduced into a cell, it may be comprised in any suitable vector, including, but not limited to, herpes simplex



viral based vectors such as pHSV1 (Geller et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:8950-8954); retroviral vectors such as MFG (Jaffee et al., 1993, Cancer Res. 53:2221-2226), and in particular Moloney retroviral vectors such as LN, LNSX, LNCX, and LXSX (Miller and Rosman, 1989, Biotechniques 7:980-989); vaccinia viral vectors such as MVA (Sutter and Moss, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10847-10851); adenovirus vectors such as pJM17 (Ali et al., 1994, Gene Therapy 1:367-384; Berker, 1988, Biotechniques 6:616-624; Wand and Finer, 1996, Nature Medicine 2:714-716); adeno-associated virus vectors such as AAV/neo (Mura-Cacho et al., 1992, J. Immunother. 11:231-237), and naked DNA vectors (International Application Publication No. WO 94/21797, by Merck et al.; International Application Publication No. WO 90/11092, by Vical et al.; United States Patent No. 5,589,466; United States Patent 5,580,859).

A KDELr inhibitor protein of the invention may be further modified, for example, to improve its half-life or activity or to alter its immunogenicity (i.e., increase or decrease the subtype of immunity elicited). In particular embodiments of the invention, a KDELr inhibitor protein of the invention may be conjugated to a second molecule, such as polyethylene glycol, or to an antigenic peptide. As a specific nonlimiting example of the latter, an antigenic peptide may be linked to one or more iterations of the N-linked glycosylation tripeptide sequence Asn-X-Thr comprised in a KDELr inhibitor protein. Expression of such a KDELr inhibitor protein/antigenic peptide complex in a lectin resistant cell line, such as 15B Chinese Hamster Ovary (CHO) cells or 1021 CHO cells, may be used to produce a mannosylated or sialylated KDELr inhibitor protein which may saturate endogenous KDEL receptors and be secreted into the surrounding culture medium. Secreted and non-secreted forms of this protein may be comprised in a vaccine formulation; by virtue of its mannosylation or sialylation, the KDELr inhibitor protein would be favored for uptake via incorporation into endosomes (Engering et al., 1997, Eur. J. Immunol. 27:2417-2425). In further embodiments of the invention, a KDELr inhibitor protein may be linked to another protein molecule as a fusion peptide or protein. As one nonlimiting example, nucleic acid encoding a KDELr inhibitor protein may be cloned at the 5' or 3' end of another molecule, using, e.g., the BamHI or KpnI restriction sites depicted in FIGURE 1A. As another nonlimiting example, a targeting sequence may be incorporated into the amino terminal region of

a KDELr inhibitor protein downstream from a cleavably removed sequence; suitable targeting sequences would include the  $\alpha_v$  integrin binding motif Arg-Gly-Asp (RGD) or Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys (SEQ ID NO:33; termed "RGD-4C"; Arap et al., 1998, Science 279:377-380). Alternatively, such a motif could be placed at a more 3' site preceding KDEL.

In a first nonlimiting example of the invention, a KDELr inhibitor protein may be formed by creating a pentamer of monomeric units, wherein each monomer comprises a COMP pentamerization domain and the protein has, at its C terminus, the amino acid sequence KDEL. FIGURE 1A depicts a nucleic acid molecule encoding one such monomeric unit, wherein a cleavable signal peptide is attached, via a linker sequence, to the pentamerization domain of rat COMP, which is in turn attached, via a linker derived from camel immunoglobulin IgG, to a C-terminal KDEL sequence. This construct may be incorporated into an expression vector, such as, but not limited to, pCDNA3, and used to produce monomers which under normal expression conditions assemble to form the pentameric KDELr inhibitor protein.

In a second nonlimiting example of the invention, a KDELr inhibitor protein may be formed by creating a trimer of monomeric units, wherein each monomer comprises a mouse thrombospondin 3 (TSP3) trimerization domain and the protein has, at its C terminus, the amino acid sequence KDEL. FIGURES 3A and 4A depict nucleic acid molecules encoding one such monomeric unit, wherein a signal peptide is attached, via a linker sequence, to the trimerization domain of mouse TSP3, which is in turn attached, via a linker derived from camel immunoglobulin IgG, to a C-terminal KDEL sequence. This construct may be incorporated into an expression vector, such as, but not limited to, pCDNA3 and used to produce monomers which under normal expression conditions assemble to form the trimeric KDELr inhibitor protein.

In a third nonlimiting example of the invention, a KDELr inhibitor protein may be formed by creating a pentamer of monomeric units, wherein each monomer comprises a human COMP pentamerization domain and the protein has, at its C terminus, the amino acid sequence KDEL. FIGURE 6A depicts a nucleic acid molecule encoding one such monomeric unit, wherein a signal peptide is attached, via a linker sequence, to the pentamerization domain of human COMP, which is in turn attached, via a linker derived from camel immunoglobulin IgG, to a C-terminal KDEL sequence. This construct may be incorporated into an expression vector, such as,

but not limited to, pCDNA3 and used to produce monomers which under normal expression conditions assemble to form the pentameric KDELr inhibitor protein.

In further related nonlimiting examples of the invention, KDELr inhibitor proteins may be prepared using constructs depicted in FIGURE 7A (using the human phospholamban oligomerization domain to produce pentamers); FIGURE 8A (using the human thrombospondin 3 oligomerization domain to produce trimers); FIGURE 9A (using the human thrombospondin 4 oligomerization domain to produce trimers); and FIGURE 5A (using the *Xenopus* thrombospondin 4 oligomerization domain to produce trimers).

## 5.2. USES OF KDEL RECEPTOR INHIBITORS

The present invention provides for a number of therapeutic and commercial uses for KDEL receptor inhibitors.

The term "KDEL receptor inhibitor", as used herein, includes but is not limited to the KDELr inhibitor proteins described in the preceding section. Non-protein molecules as well as molecules comprising a majority of non-protein elements are also encompassed by the scope of this term. Such inhibitors share the common property of inhibiting the ability of the KDEL receptor to return proteins containing a ligand sequence for the KDEL receptor to the endoplasmic reticulum. For example, KDEL receptor inhibitors may compete with the ligand sequence for binding with the KDEL receptor (*e.g.*, the oligomeric protein comprising a plurality of such ligand sequences described above), but the term includes inhibitors which act by other mechanisms as well (for example, agents which increase the ability of the KDEL receptor to release its bound proteins).

To identify KDEL receptor inhibitors, the ability of a putative inhibitor compound may be tested *in vivo* for its ability to promote the secretion of proteins which normally tend to bind to the KDEL receptor and be retained in the cell, particularly in the endoplasmic reticulum. This may be accomplished by quantitating the rate and amount of release of one or more such proteins from a cell, tissue, or cell culture in the presence and absence of putative inhibitor and/or at various concentrations of putative inhibitor. As one nonlimiting example, the distribution of a detectably labeled protein may be followed, as was done with a protein marked with an 11 amino

acid sequence derived from the human *c-myc* gene in Munro and Pelham, 1987, Cell 48:899-907.

Alternatively, KDEL receptor inhibitors may be identified by testing the ability of putative inhibitors to bind to a KDEL receptor *in vitro*. In nonlimiting embodiments, the ability of such putative KDEL inhibitors to compete with a known KDEL receptor ligand or a known KDEL receptor inhibitor for binding to a KDEL receptor may be tested. As a specific, nonlimiting example, the ability of a putative inhibitor to compete with a KDELr inhibitor protein (as described in the preceding section) for binding to a KDEL receptor may be determined. Such *in vitro* testing may desirably be performed under conditions which are similar to those found within the cell, for example, see Wilson et al., 1993, J. Biol. Chem. 268:7465-7468). Suitable sources for KDEL receptor include Golgi membrane prepared from rat liver or COS cells expressing the erd2 receptor. Putative inhibitors which appear to function as KDEL receptor inhibitors *in vitro* may then be further evaluated for their ability to inhibit KDEL receptor function *in vivo*.

As set forth above, KDEL receptor inhibitors may be used to increase the secretion of a protein which would otherwise tend to be retained in a cell by virtue of the action of the KDEL receptor, when secretion of such protein is desirable. Situations where increased secretion of a protein would be advantageous would include (i) where genetic engineering has introduced a gene encoding a protein, hereafter referred to as an "exogenous protein", into a cell, and it desirable that the exogenous protein is secreted (*e.g.*, as a specific nonlimiting example, where the exogenous protein is a heat shock protein); and (ii) where it is desirable to increase the secretion of a protein which has not been introduced by genetic engineering but which occurs in the cell either normally or as a result of a disease process such as infection or malignancy (*e.g.*, a native heat shock protein or a viral protein), hereafter referred to as an "endogenous protein".

Accordingly, the present invention provides for a method of increasing the secretion of an exogenous or endogenous protein by a cell, wherein the protein comprises a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the protein from the cell relative to the secretion of the protein in the absence of the KDEL receptor inhibitor.

In one series of nonlimiting embodiments, where it is desirable that an exogenous

protein is secreted, a nucleic acid encoding both the exogenous protein as well as a KDELr inhibitor protein (as part of the same, or distinct, nucleic acid constructs), may be introduced into a cell. According to this specific embodiment, the introduction of two distinct constructs, one encoding the desired protein and the other encoding the KDELr inhibitor protein, may be used to more accurately target the secretion of the desired protein to a particular subset of cells or tissues (that is to say, the introduced protein will be selectively secreted when both constructs are present). In related embodiments, nucleic acid encoding the desired protein and/or the KDELr inhibitor protein may be placed under the control of tissue specific or inducible promoter/enhancer elements.

In a second series of nonlimiting embodiments, where it is desirable that an endogenous protein is secreted, a KDEL receptor inhibitor, for example a KDELr inhibitor protein, may be introduced into a cell of a subject in need of such treatment, either by administration of the KDEL receptor inhibitor itself or via a nucleic acid encoding a KDELr inhibitor protein. As an example of such embodiments, heat shock proteins are known to associate with antigenic peptides to form complexes which induce an immune response to the bound peptides, and, since certain heat shock proteins tend to be selectively retained in the endoplasmic reticulum via the KDEL receptor system (including BiP and gp96), the present invention may be used to promote secretion of the antigenic heat shock protein complexes and thereby to induce or increase an immune response to a target antigen. The target antigen may be associated with an infectious disease or a cancer, including antigens associated with neoplasia such as sarcoma, lymphoma, leukemia, melanoma, carcinoma of the breast, carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix, uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma, and astrocytoma, antigens associated with defective tumor suppressor genes such as p53; antigens associated with oncogenes such as ras, src, erbB, fos, abl, and myc; antigens associated with infectious diseases caused by a bacterium, virus, protozoan, mycoplasma, fungus, yeast, parasite or prion; and antigens associated with an allergy or autoimmune disease. Examples of sources of antigens associated with infectious disease include, but are not limited to, a human papilloma virus (see below), a herpes virus such as herpes simplex or herpes zoster, a retrovirus such as human immunodeficiency virus 1 or 2, a hepatitis

virus, an influenza virus, a rhinovirus, a respiratory syncytial virus, a cytomegalovirus, an adenovirus, *Mycoplasma pneumoniae*, a bacterium of the genus *Salmonella*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Escherichia*, *Klebsiella*, *Vibrio*, or *Mycobacterium*, and a protozoan such as an amoeba, a malarial parasite, and *Trypanosoma cruzi*.

Specific, nonlimiting examples of human papilloma virus antigenic peptides which may serve as target antigens according to the invention are:

Leu-Leu-Leu-Gly-Thr-Leu-Asn-Ile-Val (SEQ ID NO: 8);

Leu-Leu-Met-Gly-Thr-Leu-Gly-Ile-Val (SEQ ID NO: 9);

Thr-Leu-Gln-Asp-Ile-Val-Leu-His-Leu (SEQ ID NO: 10);

Gly-Leu-His-Cys-Tyr-Glu-Gln-Leu-Val (SEQ ID NO: 11); and

Pro-Leu-Lys-Gln-His-Phe-Gln-Ile-Val (SEQ ID NO: 12).

Accordingly, the present invention relates to a method for promoting the release of a heat shock protein/antigenic peptide complex from a cell, where the heat shock protein contains a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the complex from the cell relative to the secretion of the complex in the absence of the KDEL receptor inhibitor. Where the KDEL receptor inhibitor is a protein, it may be administered as a protein or as a nucleic acid encoding said KDELr inhibitor protein (using "genetic vaccination techniques" including, but not limited to, techniques whereby "naked DNA" encoding the KDELr inhibitor protein is administered to a subject).

In related embodiments, the present invention further provides for a method of inducing or increasing an immune response to a target antigen, comprising administering an effective amount of a KDEL receptor inhibitor, where the target antigen forms a complex with a heat shock protein and the heat shock protein contains a ligand sequence which binds to a KDEL receptor. The target antigen may be an endogenous antigen or may be introduced, either by an encoding nucleic acid or in peptide form. Similarly, the heat shock protein may be an endogenous heat shock protein or may be introduced by gene therapy techniques.

In a specific, nonlimiting embodiment, the present invention envisions the use of a KDEL receptor inhibitor which may be used to boost immunity in a subject in need of such

treatment; examples would include a subject at risk of developing a cancer in view of a genetic predisposition or carcinogen exposure, or a subject at risk for developing infection in view of a compromised immune system and/or pathogen exposure. Under circumstances where the antigen has not yet been identified, immunity may be induced toward endogenous antigen(s). Where target antigen(s) is (are) known, a KDEL receptor inhibitor may be administered in conjunction with a target antigen, which may be comprised in a vaccine administered by any standard route (e.g., subcutaneously, intramuscularly, intranasally, etc.). An orally administered KDEL receptor inhibitor may be particularly advantageous.

Because systemic administration of a KDEL receptor inhibitor may be expected to transiently induce widespread release of proteins normally retained in the endoplasmic reticulum, it may be desirable to administer a KDEL receptor inhibitor having a short half-life at intervals which minimize any toxic effects, for example, but not by way of limitation, one dose every two weeks for a month. Alternatively, a KDEL receptor inhibitor may be locally administered to a site containing endogenous antigen (for example, a malignant tumor or infected tissue) or a site containing exogenous antigen (for example, but not by way of limitation, a site wherein nucleic acid encoding target antigen has been administered).

The present invention further provides for a non-human transgenic animal carrying, as a transgene, in all or a subpopulation of the cells of the animal, nucleic acid encoding an exogenous KDELr inhibitor protein (as distinct from KDEL-bearing proteins normally present in the animal), operably linked to a promoter sequence. In preferred nonlimiting embodiments of the invention, the promoter is an inducible promoter. Such a transgenic animal may be used to study the effects of promoting the secretion of an endogenous or exogenously introduced protein of interest.

Where a protein comprising a ligand sequence for a KDEL receptor is being commercially produced, a KDEL receptor inhibitor of the invention may be used to promote secretion of the protein and therefore facilitate its manufacture.

Accordingly, the present invention provides for compositions comprising a KDEL receptor inhibitor, or a nucleic acid encoding a KDEL receptor inhibitor, in a suitable pharmaceutical carrier. Such compositions may further comprise a target antigen or a nucleic

acid encoding a target antigen or a precursor of a target antigen which is processed in a cell to yield a target antigen, a nucleic acid encoding a heat shock protein, a cytokine which promotes the activity of the immune system, such as interleukin 2 and/or alpha interferon, and/or an agent which facilitates protein secretion, such as monensin.

For illustrative purposes only, specific, nonlimiting embodiments of the invention may be practiced as follows.

#### 1. Expression And Purification Of Recombinant rCOMP-KDELr Inhibitor Proteins.

Rat COMP-KDELr inhibitor protein encoded by a pet 11-derived plasmid prepared using the construct depicted in FIGURE 1A, under the control of the T7 promoter, may be expressed in *E. coli* BL21 (DE3) cells, according to the method described in Efimov et al., 1994, FEBS Letts. 341:54-58. Vector-containing bacteria may be cultured in shaker flasks at 37°C to an OD<sub>600</sub> of approximately 0.5 - 0.6, and then 1.0 mM isopropyl β-D-thiogalactoside may be added per liter of culture to induce protein synthesis. After further incubation for about four hours at 30°C, bacterial cells may be harvested by centrifugation at 8000 x g for 15 minutes at 4°C. Bacterial pellets may then be resuspended in 20 ml TE buffer (20mM Tris-HCl, pH 8.0, 1mM EDTA) containing 0.1 mg/ml lysozyme, and then incubated at 25°C or room temperature for about 30 minutes. Alternatively, bacterial cells may be lysed using a cell disruptor such as Emulsiflex C-5 (Avestin, Ontario, Canada). The resulting cell lysate may be incubated with 0.1 mg/ml DNAase I for 15 minutes at 25°C (room temperature) and then centrifuged at 23,000 x g at 4°C for fifteen minutes to remove insoluble material. These conditions may also be used for subsequent centrifugations. Two milliliters of 30 percent w/v streptomycin sulfate solution may be mixed with the resulting supernatant and the mixture may be incubated on ice for 15 minutes. The resulting precipitate may be removed by centrifugation and ammonium sulfate may be added to the supernatant to about 36 percent saturation, and the solution may be incubated on ice for about 15 minutes to produce an ammonium sulfate/protein precipitate. The ammonium sulfate/protein precipitate may then be collected by centrifugation as set forth above. The pellet obtained by centrifugation may be resuspended in 2 ml TE buffer and applied to a 10 ml hydroxylapatite column (BioRad, DNA grade), pre-equilibrated with 10 mM sodium phosphate, pH 7.6. The column may be washed with the pre-equilibration buffer having an increasing



phosphate gradient, and the flow-through protein fraction, which would be expected to contain mainly the recombinant rCOMP-KDELr inhibitor protein, may be collected. Analogous methods may be used to purify KDELr inhibitor protein expressed in 15B CHO cells or insect cells.

Oligomerization of the recombinantly expressed protein may be achieved as follows, using a method as described in Efimov et al., 1994, FEBS Letts. 341:54-58. Purified KDELr inhibitor protein may be substantially (preferably completely) reduced by incubation with a 100-fold molar excess of dithiothreitol (DTT) for about 30 minutes at 37°C, followed by precipitation with 50 percent ammonium sulfate, followed by centrifugation as set forth above. The resulting pellet may be resuspended in 0.2 M Tris-HCl, pH 8.8, 0.2 M NaCl, 1 mM EDTA to a final protein concentration of 1.5 mg/mL. The protein may be oxidized at room temperature by addition of oxidized and reduced glutathione to final concentrations of 10 mM and 2 mM respectively over a period of about 14 hours. The oxidized protein may then be separated from glutathione by HPLC or dialysis. The correctly folded pentamer may also be purified by reverse phase chromatography on a C4 column.

The KDELr inhibitor protein may also be oligomerized by the method described in Jaenicke and Rudolph, 1989, in Creighton et al., *Protein Structure: a practical approach*. IRL Press Oxford, pp. 208-209, wherein the protein may be first reduced by incubation for 2 hours in 0.1 M DTT, 6 M guanidine hydrochloride, 1 mM EDTA and 0.1 M Tris-HCl, pH 8.3, followed by acidification and dialysis overnight at 4°C against 0.01 M HCl, and then refolded for about 16 hours at 16°C in an oxido-shuffling system containing 0.3 mM cystine and 3 mM cysteine, 1 mM EDTA and 0.1 M Tris-HCL, pH 8.3. The protein may subsequently be purified by HPLC, lyophilized and stored at 4°C.

## 2. Testing The Ability of KDEL Receptor Inhibitor To Bind To KDEL Receptor.

The ability of KDEL receptor inhibitors of the invention to bind to KDEL receptor may be tested *in vitro* using alkali-washed Golgi membranes. Such membranes may be prepared from livers of freshly sacrificed rats using the methods described by Tabas and Kornfeld, 1979, J. Biol. Chem. 254:11655-11663, or from cultured cells expressing erd 2 receptors in their Golgi membranes. For example, harvested liver or cultured cells may be

dounced and used to prepare a 1500 x g postnuclear supernatant, which may then be spun at 100,000 x g to recover a crude membrane fraction. The resulting crude membranes may then be washed with 100 mM Na<sub>2</sub>CO<sub>3</sub> at 4°C, pelleted by centrifugation at 100,000 x g, and then resuspended in 10 mM HEPES-KOH, pH 7.5 to produce alkali-washed Golgi membrane.

The alkali-washed Golgi membrane may then be used in a binding assay as described by Wilson et al., 1993, J. Biol. Chem. 268:7465-7468 to determine whether a putative KDEL receptor inhibitor binds to the erd 2 (KDEL) receptor. The ability of a putative KDEL receptor inhibitor to bind to the erd 2 receptor may be determined by measuring the ability of the inhibitor to compete with a detectably labeled peptide which binds the erd 2 receptor, such as Tyr-Thr-Ser-Glu-Lys-Asp-Glu-Leu (SEQ ID NO:31) or Leu-Asn-Tyr-Phe-Asp-Asp-Glu-Leu (SEQ ID NO:32) for receptor binding. Such peptides may, for example, be radioiodinated by incubation with 1 mCi of [<sup>125</sup>I] iodide for one minute in the presence of 2.4 mg/ml of chloramine T (BDH Chemicals, Ltd.) quenched and the iodinated peptides may be separated on a Sephadex G-10 column (Pharmacia) as described in Harlow and Lane, 1988, in *Antibodies: a laboratory manual*, Cold Spring Harbor Press, Cold Spring Harbor, NY. The binding assay buffer may contain 20 mM NaCl, 250 mg/ml bovine serum albumin, 50 mM sodium or potassium cacodylate or citrate, pH 5.0-5.5, MES (2-[N-morpholino]ethane sulfonic acid) or a mixture of succinate and PIPES (piperazine-N,N'-bis[2-ethanesulfonic acid) at the same molarity. Putative KDEL receptor inhibitor at various concentrations, total membrane protein (for example 0.5-1.0 µg), radiolabeled peptide (for example, 0.1-0.5 ng peptide having 1 x 10<sup>5</sup> cpm) and alkali-washed Golgi membrane at 2-4 percent w/v may be incubated in (e.g., 25 µl) binding assay buffer at 4°C for about 20 minutes, and then centrifuged in a microfuge (at about 15,800 x g) at 4°C for 5 minutes, and the amount of labeled peptide present in the pellet may be determined. An observed decrease in bound labeled peptide with increasing concentrations of putative KDEL receptor inhibitor indicates that the putative KDEL receptor inhibitor is binding to the erd 2 receptor.

### 3. Introduction Of rCOMP/KDELr Inhibitor Protein Into Tumor Cells.

A 375 base pair Hind III - Xho I fragment of a partial gene construct encoding a cleavable signal peptide (such as the signal peptide from the murine heat shock protein BiP) at

the 5' end linked to the rat COMP pentamerization domain followed by the camel IgG domain (see FIGURE 1A) may be synthesized (for example, by a commercial entity such as Oligos, Etc., Inc., Oregon). The resulting fragment may be cloned into a mammalian expression vector such as pCDNA3 by standard techniques (see, for example, Sambrook et al., 1990, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY), using the Hind III - Xho I restriction sites and transformed into TOP10F' competent cells (which may be obtained from InVitrogen, Inc.). The sequences of the resulting plasmid, rCOMP/pCDNA3 may be verified by dideoxy sequencing (Sanger et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467) using Sequenase 2.0 (United States Biochemical).

A 72 base pair double-stranded KDEL-containing oligonucleotide may then be annealed at the 3' end of rCOMP-pCDNA3 using the Kpn I- Eco RI restriction endonuclease site (see FIGURE 1A) to generate rCOMP-KDELr inhibitor/pCDNA3. This construct may then be verified by dideoxynucleotide sequencing.

The construct rCOMP-KDELr inhibitor/pCDNA3 may then be expressed, for example, in a tumor cell line such as CMS-5. CMS-5 is a methylcholanthrene-induced fibrosarcoma of BALB/c origin, shown to be devoid of viral antigens (DeLeo et al., 1977, J. Exp. Med. 146:720-734). CMS-5 cells may be adapted to culture and grown in DMEM medium (Gibco Life Technologies, Inc.) supplemented with 10% fetal calf serum (FCS). Transfection may be carried out using lipofectamine, according to the manufacturer's instructions (Gibco-BRL Life Technologies). Briefly, 2 $\mu$ g of cDNA and 6 $\mu$ L of lipofectamine may be diluted separately into 100  $\mu$ L serum-free medium (OPTI-MEM® I Reduced Serum medium, Gibco-BRL Life Technologies). The two solutions may then be mixed and incubated at room temperature for about 45 minutes to allow the formation of DNA-liposome complexes. 800  $\mu$ L of OPTI-MEM® may be added to the resulting complexes, mixed, and overlaid onto rinsed cells. After an approximately six hour incubation period at 37°C, one milliliter of growth medium containing 20% FCS may be added. Fresh medium may be added to the cells 24 hours post-transfection. Stable clones may be selected by adding 800  $\mu$ g/ml geneticin (Gibco-BRL Life Technologies) to the cells 72 hours later. The selection medium may be changed about every three days. Colonies of stably transfected cells may be screened for expression of

rCOMP/KDELr inhibitor proteins using antiserum raised against bovine COMP (Hedbom et al., 1992, J. Biol. Chem. 264:6898-6905). This antibody has been shown to stain rat COMP under both nonreducing as well as reducing conditions (Morgelin et al., 1992, J. Biol. Chem. 267:6137-6141).

Stably transfected tumor cells produced in this manner may be utilized in a number of ways. For example, they may be used to determine whether increased secretion of a particular protein, normally retained by the KDEL receptor, may effect the tumorigenicity of the cells. In one specific nonlimiting example, they may be used to determine whether the secretion of an endogenous heat shock protein is increased and whether the increased secretion of endogenous protein decreases the tumorigenicity of the cells (*e.g.*, stably transfected CMS-5 cells described above may be inoculated into CB6F-1/J mice). In another specific nonlimiting example, stably transfected tumor cells may further be transfected with nucleic acid encoding an exogenous protein, and it may be determined whether increased secretion of the exogenous protein by the tumor cells decreases their tumorigenicity.

Various references are cited herein, the contents of which are hereby incorporated by reference in their entireties.

# SEQUENCE LISTING

<110> Rothman, James  
Mayhew, Mark  
Hoe, Mee

<120> KDEL RECEPTOR INHIBITORS

<130> 31488

<160> 36

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 46

<212> PRT

<213> rat

<400> 1

Gly	Asp	Leu	Ala	Pro	Gln	Met	Leu	Arg	Glu	Leu	Gln	Glu	Thr	Asn	Ala
1			5					10						15	
Ala	Leu	Gln	Asp	Val	Arg	Glu	Leu	Leu	Arg	Gln	Gln	Val	Lys	Glu	Ile
		20					25						30		
Thr	Phe	Leu	Lys	Asn	Thr	Val	Met	Glu	Cys	Asp	Ala	Cys	Gly		
		35					40					45			

<210> 2

<211> 46

<212> PRT

<213> human

<400> 2

Ser	Asp	Leu	Gly	Pro	Gln	Met	Leu	Arg	Glu	Leu	Gln	Glu	Thr	Asn	Ala
1			5					10						15	
Ala	Leu	Gln	Asp	Val	Arg	Asp	Trp	Leu	Arg	Gln	Gln	Val	Arg	Glu	Ile
		20					25						30		
Thr	Phe	Leu	Lys	Asn	Thr	Val	Met	Glu	Cys	Asp	Ala	Cys	Gly		
		35					40					45			

<210> 3

<211> 46

<212> PRT

<213> mouse

<400> 3

Gly	Glu	Gln	Thr	Lys	Ala	Leu	Val	Thr	Gln	Leu	Thr	Leu	Phe	Asn	Gln
1			5					10						15	
Ile	Leu	Val	Glu	Leu	Arg	Asp	Asp	Ile	Arg	Asp	Gln	Val	Lys	Glu	Met

20                      25                      30  
 Ser Leu Ile Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly  
 35                      40                      45

<210> 4  
 <211> 46  
 <212> PRT  
 <213> human

<400> 4  
 Gly Glu Gln Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln  
 1                      5                      10                      15  
 Ile Leu Val Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met  
 20                      25                      30  
 Ser Leu Ile Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly  
 35                      40                      45

<210> 5  
 <211> 46  
 <212> PRT  
 <213> human

<400> 5  
 Gly Asp Phe Asn Arg Gln Phe Leu Gly Gln Met Thr Gln Leu Asn Gln  
 1                      5                      10                      15  
 Leu Leu Gly Glu Val Lys Asp Leu Leu Arg Gln Gln Val Lys Glu Thr  
 20                      25                      30  
 Ser Phe Leu Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly  
 35                      40                      45

<210> 6  
 <211> 46  
 <212> PRT  
 <213> xenopus laevis

<400> 6  
 Gly Asp Val Ser Arg Gln Leu Ile Gly Gln Ile Thr Gln Met Asn Gln  
 1                      5                      10                      15  
 Met Leu Gly Glu Leu Arg Asp Val Met Arg Gln Gln Val Lys Glu Thr  
 20                      25                      30  
 Met Phe Leu Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly  
 35                      40                      45

<210> 7  
 <211> 27  
 <212> PRT  
 <213> human

<400> 7  
 Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys  
 1                      5                      10                      15

Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu  
20 25

<210> 8  
<211> 9  
<212> PRT  
<213> human papilloma virus

<400> 8  
Leu Leu Leu Gly Thr Leu Asn Ile Val  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> human papilloma virus

<400> 9  
Leu Leu Met Gly Thr Leu Gly Ile Val  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> human papilloma virus

<400> 10  
Thr Leu Gln Asp Ile Val Leu His Leu  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> human papilloma virus

<400> 11  
Gly Leu His Cys Tyr Glu Gln Leu Val  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> human papilloma virus

<400> 12  
Pro Leu Lys Gln His Phe Gln Ile Val  
1 5

<210> 13  
<211> 115  
<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric rat comp

<400> 13

```
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1           5           10           15
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Leu Ala Pro Gln Met
      20           25           30
Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp Val Arg Glu
      35           40           45
Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys Asn Thr Val
      50           55           60
Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr Pro Gly Thr
65           70           75           80
Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro
      85           90           95
Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys
      100          105          110
Asp Glu Leu
      115
```

<210> 14

<211> 387

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric rat COMP-KDEL

<400> 14

```
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg      60
cgggcccagg gatccagcct ggggtggagac ctagcccccac agatgcttcg agaactccag      120
gagactaatg cggcgctgca agacgtgaga gagctcttgc gacagcaggt caaggagatc      180
accttcctga agaatacggg gatggaatgt gacgcttgcg gaatgcagcc cgcacgcacc      240
cccgttacta gtccgcagcc gcagccgaaa ccgcagccgc agccgcagcc gcagccgaaa      300
ccgcagccga aaccggaacc ggaagggtacc ggatcatcag aaaaagatga gttgtaggcg      360
gccgcagaat tccatatgca tctcgag                                     387
```

<210> 15

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric rat COMP-KDEL

<400> 15

```
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1           5           10           15
```



Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Pro Gln Met  
20 25 30  
Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp Val Arg Glu  
35 40 45  
Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys Asn Thr Val  
50 55 60  
Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr Pro Gly Thr  
65 70 75 80  
Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro  
85 90 95  
Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys  
100 105 110  
Asp Glu Leu  
115

<210> 16  
<211> 387  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> chimeric rat COMP-KDEL

<400> 16  
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
cgggccgagg gatccagcct ggggtggagac tggtgtccac agatgcttcg agaactccag 120  
gagactaatg cggcgctgca agacgtgaga gagctcttgc gacagcaggt caaggagatc 180  
accttcctga agaatacggg gatggaatgt gacgcttgcg gaatgcagcc cgcacgcacc 240  
cccgtacta gtccgcagcc gcagccgaaa ccgcagccgc agccgcagcc gcagccgaaa 300  
ccgcagccga aaccggaacc ggaaggtacc ggatcatcag aaaaagatga gttgtaggcg 360  
gccgcagaat tccatatgca tctcag 387

<210> 17  
<211> 105  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> chimeric mouse TSP3-KDEL

<400> 17  
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
1 5 10 15  
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Lys Ala Leu  
20 25 30  
Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val Glu Leu Arg Asp  
35 40 45  
Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile Arg Asn Thr Ile  
50 55 60  
Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro Lys Pro Gln Pro  
65 70 75 80

Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly  
                     85                    90                    95  
 Thr Gly Ser Ser Glu Lys Asp Glu Leu  
                     100                    105

<210> 18  
 <211> 357  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric mouse TSP3-KDEL

<400> 18  
 aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
 cgggccgagg gatccagcct gggaggagac tgttgtaagg cattggtcac ccagctcacc 120  
 ctcttcaacc agatcctagt ggagcttcgg gacgacatcc gagaccaggt gaaggaaatg 180  
 tcaactcatcc ggaacacccat catggagtgt cagggtgtgcg gtccgcagcc gcagccgaaa 240  
 ccgcagccgc agccgcagcc gcagccgaaa ccgcagccga aaccggaacc ggaagggtacc 300  
 ggatcatcag aaaaagatga gttgtaggcg gccgcagaat tccatatgca tctcgag 357

<210> 19  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric mouse TSP3-KDEL

<400> 19  
 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
   1                    5                    10                    15  
 Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Glu Gln  
                     20                    25                    30  
 Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val  
                     35                    40                    45  
 Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile  
   50                    55                    60  
 Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro  
   65                    70                    75                    80  
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
                     85                    90                    95  
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
                     100                    105

<210> 20  
 <211> 369  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> chimeric mouse TSP3-KDEL

<400> 20

```
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg      60
cgggccgagg gatccagcct ggggtggagac tgttggtggg agcagaccaa ggcattggtc      120
accagctca ccctcttcaa ccagatccta gtggagcttc gggacgacat ccgagaccag      180
gtgaaggaaa tgtcactcat ccggaacacc atcatggagt gtcagggtgtg cgggtccgcag      240
ccgcagccga aaccgcagcc gcagccgcag ccgcagccga aaccgcagcc gaaaccggaa      300
ccggaaggta ccggatcatc agaaaaagat gagttgtagg cggccgcaga attccatatt      360
catctcgag                                     369
```

<210> 21

<211> 109

<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric Xenopus laevis TSP4-KDEL

<400> 21

```
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1           5           10           15
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Asp Val
      20           25           30
Ser Arg Gln Leu Ile Gly Gln Ile Thr Gln Met Asn Gln Met Leu Gly
      35           40           45
Glu Leu Arg Asp Val Met Arg Gln Gln Val Lys Glu Thr Met Phe Leu
      50           55           60
Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly Pro Gln Pro Gln Pro
      65           70           75           80
Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro
      85           90           95
Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu
      100           105
```

<210> 22

<211> 369

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric Xenopus laevis TSP4-KDEL

<400> 22

```
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg      60
cgggccgagg gatccagcct ggggtggagac tgttggtggg acgtcagcag acagttgatt      120
ggccagataa cccaaatgaa tcagatgctg ggagagctcc gagatgtcat gagacagcag      180
gtgaaagaga ccatgttctt gagaaacacc attgcagaat gccaggcctg tggcccgag      240
ccgcagccga aaccgcagcc gcagccgcag ccgcagccga aaccgcagcc gaaaccggaa      300
ccggaaggta ccggatcatc agaaaaagat gagttgtagg cggccgcaga attccatatt      360
catctcgag                                     369
```

<210> 23  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human COMP-KDEL

<400> 23  
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser  
 1 5 10 15  
 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Ser Asp Leu  
 20 25 30  
 Gly Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln  
 35 40 45  
 Asp Val Arg Asp Trp Leu Arg Gln Gln Val Arg Glu Ile Thr Phe Leu  
 50 55 60  
 Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly Pro Gln Pro Gln Pro  
 65 70 75 80  
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
 85 90 95  
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
 100 105

<210> 24  
 <211> 372  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human COMP-KDEL

<400> 24  
 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgcggc agtctgcagc 60  
 gctgccaaaa aaggatccag cctgggtgga gactgttggt cagacctggg cccgcagatg 120  
 cttcggaac tgcaggaaac caacgcggcg ctgcaggacg tgcgggaactg gctgcggcag 180  
 caggtcaggg agatcacgtt cctgaaaaac acggtgatgg agtgtgacgc gtgcggggccg 240  
 cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg 300  
 gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat 360  
 atgcatctcg ag 372

<210> 25  
 <211> 90  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human PLB-KDEL

<400> 25  
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser

1 5 10 15  
 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gln Lys Leu  
 20 25 30  
 Gln Asn Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu  
 35 40 45  
 Ile Cys Ile Ile Val Met Leu Leu Pro Gln Pro Gln Pro Lys Pro Gln  
 50 55 60  
 Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu  
 65 70 75 80  
 Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
 85 90

<210> 26  
 <211> 315  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human PLB-KDEL

<400> 26  
 aagcttacca tgggaaggtta catgatttta ggcttgctcg cccttgcggc agtctgcagc 60  
 gctgccaaaa aaggatccag cctgggtgga gactgttgtc aaaagctaca gaatctattt 120  
 atcaatttct gtctcatctt aatatgtctc ttgetgatct gtatcatcgt gatgcttctc 180  
 ccgcagccgc agccgaaacc gcagccgcag ccgcagccgc agccgaaacc gcagccgaaa 240  
 ccggaaccgg aaggtaccgg atcatcagaa aaagatgagt tgtaggcggc cgcagaattc 300  
 catatgcattc tcgag 315

<210> 27  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human TSP3-KDEL

<400> 27  
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser  
 1 5 10 15  
 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Glu Gln  
 20 25 30  
 Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val  
 35 40 45  
 Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile  
 50 55 60  
 Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro  
 65 70 75 80  
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
 85 90 95  
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
 100 105

<210> 28  
 <211> 372  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human TSP3-KDEL

<400> 28  
 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccggc agtctgcagc 60  
 gctgccaaaa aaggatccag cctgggtgga gactgtgtg gggagcagac caaggcattg 120  
 gtcaccacagc tcacctctt caaccagatc ctagtggagc ttcgggacga catccgagac 180  
 caggtgaagg aaatgtcact catccggaac accatcatgg agtgtcaggt gtgcggtccg 240  
 cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg 300  
 gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat 360  
 atgcatctcg ag 372

<210> 29  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human TSP4-KDEL

<400> 29  
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser  
 1 5 10 15  
 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Asp Phe  
 20 25 30  
 Asn Arg Gln Phe Leu Gly Gln Met Thr Gln Leu Asn Gln Leu Leu Gly  
 35 40 45  
 Glu Val Lys Asp Leu Leu Arg Gln Gln Val Lys Glu Thr Ser Phe Leu  
 50 55 60  
 Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly Pro Gln Pro Gln Pro  
 65 70 75 80  
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
 85 90 95  
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
 100 105

<210> 30  
 <211> 372  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human TSP4-KDEL

<400> 30  
 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccggc agtctgcagc 60

gctgccaaaa	aaggatccag	cctgggtgga	gactgttgtg	gggacttta	ccggcagttc	120
ttgggtcaaa	tgacacaatt	aaaccaactc	ctgggagagg	tgaaggacct	tctgagacag	180
cagggttaagg	aaacatcatt	tttgcgaaac	accatagctg	aatgccaggc	ttgcggtccg	240
cagccgcagc	cgaaaccgca	gccgcagccg	cagccgcagc	cgaaaccgca	gccgaaaccg	300
gaaccggaag	gtaccggatc	atcagaaaaa	gatgagttgt	aggcggccgc	agaattccat	360
atgcatctcg	ag					372

<210> 31  
 <211> 8  
 <212> PRT  
 <213> unknown

<400> 31  
 Tyr Thr Ser Glu Lys Asp Glu Leu  
 1 5

<210> 32  
 <211> 8  
 <212> PRT  
 <213> unknown

<400> 32  
 Leu Asn Tyr Phe Asp Asp Glu Leu  
 1 5

<210> 33  
 <211> 9  
 <212> PRT  
 <213> unknown

<400> 33  
 Cys Asp Cys Arg Gly Asp Cys Phe Cys  
 1 5

<210> 34  
 <211> 134  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> KDEL/myc

<400> 34  
 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
 1 5 10 15  
 Val Arg Ala Glu Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
 20 25 30  
 Tyr His Pro Asn Ser Thr Cys Gly Ser Ser Leu Gly Gly Asp Cys Cys  
 35 40 45  
 Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp  
 50 55 60

Val Arg Glu Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys  
65 70 75 80  
Asn Thr Val Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr  
85 90 95  
Pro Gly Thr Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln  
100 105 110  
Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser  
115 120 125  
Ser Glu Lys Asp Glu Leu  
130

<210> 35  
<211> 444  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> KDEL-myc

<400> 35  
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
cgggccgagg gatccgaaca aaaacttatt tctgaagaag acttgtagca cccaaactca 120  
acatgcggat ccagcctggg tggagactgt tgtccacaga tgcttcgaga actccaggag 180  
actaatgcgg cgctgcaaga cgtgagagag ctcttgcgac agcaggtcaa ggagatcacc 240  
ttcctgaaga atacggtgat ggaatgtgac gcttgcgga tgcagccgc acgcaccccc 300  
ggtactagtc cgcagccgca gccgaaaccg cagccgcagc cgcagccgca gccgaaaccg 360  
cagccgaaac cggaaccgga aggtaccgga tcatcagaaa aagatgagtt gtaggcggcc 420  
gcagaattcc atatgcatct cgag 444

<210> 36  
<211> 10  
<212> PRT  
<213> human myc tag

<400> 36  
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
1 5 10



WHAT IS CLAIMED IS:

1. An oligomeric KDEL receptor inhibitor protein comprising a plurality of protein subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor.
2. The KDEL receptor inhibitor protein of claim 1, wherein the region which binds to a KDEL receptor has the amino acid sequence Lys-Asp-Glu-Leu.
3. The KDEL receptor inhibitor protein of claim 1, wherein the oligomerization domain is a pentamerization domain.
4. The KDEL receptor inhibitor protein of claim 2, wherein the oligomerization domain is a pentamerization domain.
5. The KDEL receptor inhibitor protein of claim 3, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.
6. The KDEL receptor inhibitor protein of claim 1, wherein the oligomerization domain is derived from a thrombospondin protein.
7. The KDEL receptor inhibitor protein of claim 5, wherein the pentamerization domain has the amino acid sequence Gly-Asp-Leu-Ala-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Glu-Leu-Leu-Arg-Gln-Gln-Val-Lys-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO: 1).
8. The KDEL receptor inhibitor protein of claim 5, wherein the pentamerization domain has the amino acid sequence Ser-Asp-Leu-Gly-Pro-Gln-Met-Leu-Arg-Glu-Leu-Gln-Glu-Thr-Asn-Ala-Ala-Leu-Gln-Asp-Val-Arg-Asp-Trp-Leu-Arg-Gln-Gln-Val-Arg-Glu-Ile-Thr-Phe-Leu-Lys-Asn-Thr-Val-Met-Glu-Cys-Asp-Ala-Cys-Gly (SEQ ID NO:2).
9. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:3).
10. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Glu-Gln-Thr-Lys-Ala-Leu-Val-Thr-Gln-Leu-Thr-Leu-Phe-Asn-Gln-Ile-Leu-Val-Glu-Leu-Arg-Asp-Asp-Ile-Arg-Asp-Gln-Val-Lys-Glu-Met-Ser-Leu-

Ile-Arg-Asn-Thr-Ile-Met-Glu-Cys-Gln-Val-Cys-Gly (SEQ ID NO:4).

11. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Asp-Phe-Asn-Arg-Gln-Phe-Leu-Gly-Gln-Met-Thr-Gln-Leu-Asn-Gln-Leu-Leu-Gly-Glu-Val-Lys-Asp-Leu-Leu-Arg -Gln-Gln-Val-Lys-Glu-Thr-Ser-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:5).

12. The KDEL receptor inhibitor protein of claim 6, wherein the oligomerization domain has the amino acid sequence Gly-Asp-Val-Ser-Arg-Gln-Leu-Ile-Gly-Gln-Ile-Thr-Gln-Met-Asn-Gln-Met-Leu-Gly-Glu-Leu-Arg-Asp-Val-Met-Arg-Gln-Gln-Val-Lys-Glu-Thr-Met-Phe-Leu-Arg-Asn-Thr-Ile-Ala-Glu-Cys-Gln-Ala-Cys-Gly (SEQ ID NO:6).

13. The KDEL receptor inhibitor protein of claim 1, wherein the oligomerization domain has the amino acid sequence Gln-Lys-Leu-Gln-Asn-Leu-Phe-Ile-Asn-Phe-Cys-Leu-Ile-Leu-Ile-Cys-Leu-Leu-Leu-Ile-Cys-Ile-Ile-Val-Met-Leu-Leu (SEQ ID NO:7).

14. An isolated nucleic acid encoding a KDEL receptor inhibitor of claim 1.

15. An isolated nucleic acid encoding a KDEL receptor inhibitor of claim 2.

16. An isolated nucleic acid encoding a KDEL receptor inhibitor of claim 3.

17. An isolated nucleic acid encoding a KDEL receptor inhibitor of claim 4.

18. An isolated nucleic acid encoding a KDEL receptor inhibitor of claim 5.

19. An isolated nucleic acid encoding a KDEL receptor inhibitor of claim 6.

20. A method of increasing the secretion of a protein by a cell, wherein the protein comprises a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the protein from the cell relative to the secretion of the protein in the absence of the KDEL receptor inhibitor.

21. The method of claim 20, wherein the KDEL receptor inhibitor is an oligomeric KDEL receptor inhibitor protein comprising a plurality of protein subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor.

22. The method of claim 21, wherein the region of the KDEL inhibitor protein which binds to a KDEL receptor has the amino acid sequence Lys-Asp-Glu-Leu.

23. The method of claim 21, wherein the oligomerization domain of the KDEL

inhibitor protein is a pentamerization domain.

24. The method of claim 22, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

25. The method of claim 23, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

26. The method of claim 21, wherein the oligomerization domain is derived from a thrombospondin protein.

27. The method of claim 24, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

28. The method of claim 22, wherein the oligomerization domain is derived from a thrombospondin protein.

29. A method for promoting the release of a heat shock protein/antigenic peptide complex from a cell, where the heat shock protein contains a ligand sequence which binds to a KDEL receptor, comprising exposing the cell to a KDEL receptor inhibitor at a concentration which increases the secretion of the complex from the cell relative to the secretion of the complex in the absence of the KDEL receptor inhibitor.

30. The method of claim 29, wherein the KDEL receptor inhibitor is an oligomeric KDEL receptor inhibitor protein comprising a plurality of protein subunits, wherein each subunit comprises an oligomerization domain and has, at its carboxy terminus, a region which binds to a KDEL receptor.

31. The method of claim 30, wherein the region of the KDEL inhibitor protein which binds to a KDEL receptor has the amino acid sequence Lys-Asp-Glu-Leu.

32. The method of claim 30, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

33. The method of claim 31, wherein the oligomerization domain of the KDEL inhibitor protein is a pentamerization domain.

34. The method of claim 32, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

35. The method of claim 30, wherein the oligomerization domain is derived from

a thrombospondin protein.

36. The method of claim 33, wherein the pentamerization domain is derived from a cartilage oligomeric matrix protein.

37. The method of claim 31, wherein the oligomerization domain is derived from a thrombospondin protein.

38. A method of inducing or increasing an immune response to a target antigen, comprising administering, to a subject in need of such treatment, an effective amount of a KDEL receptor inhibitor, where the target antigen forms a complex with a heat shock protein and the heat shock protein contains a ligand sequence which binds to a KDEL receptor.

39. The method of claim 38 wherein the target antigen is an endogenous antigen.

40. The method of claim 38 wherein the target antigen is an antigen which has been introduced into the subject.

41. The method of claim 38 wherein the heat shock protein is an endogenous heat shock protein.

42. The method of claim 38 wherein the heat shock protein has been introduced into the subject by the administration of a nucleic acid encoding the heat shock protein.

43. A non-human transgenic animal carrying a transgene encoding the KDEL receptor inhibitor protein of claim 1 operably linked to a promoter sequence.

### ABSTRACT

The present invention relates to inhibitors of the KDEL receptor and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a KDEL receptor inhibitor promotes the secretion of such proteins. In specific embodiments of the invention, KDEL receptor inhibitors may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.

**A.**



MGKFTVVA AALLLGAVRAE-GSS -

[illegible]

31488 (sheet 2 of 25)

FIGURE 1C.

Bbr I      EcoP15 I  
Hind III    Nco I      EcoP15 I

AAGCTTACCAATGGGAAAGTTCACTGTGGTGGCGGCGGCGTTGCTGCTGCTGGGCGCGGTG 60

M G K F T V V A A A L L L L G A V

BamH I      Bsa I      Bpm I      RleA I  
Taq II'

CGGGCCGAGGGATCCAGCCTGGGTGGAGACCTAGCCCCACAGATGCTTCGAGAACTCCAG 120

R A E G S S L G G D L A P Q M L R E L Q

EcoICR I      Sac I      BspM I      EclHK I      BstZ2 I

GAGACTAATGCGGCGCTGCAAGACGTGAGAGAGCTCTTGCGACAGCAGGTCAAGGAGATC 180

E T N A A L Q D V R E L L R Q Q V K E I

EcoP15 I      Eco57 I      BsaM I

ACCTTCCTGAAGAATACGGTGATGGAATGTGACGCTTGCGGAATGCAGCCCGCACGCACC 240

T F L K N T V M E C D A C G M Q P A R T

31488 (sheet 3 of 3)

Spe I

CCCGGTACTAGTCCGCAGCCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAA

300

P G T S P Q P Q P K P Q P Q P Q P Q P K

Acc65 I

Kpn I

Eco52 I

CCGCAGCCGAAACCGGAACCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTG TAG GCG

360

P Q P K P E P E G T G S S E K D E L .

FIGURE 1D.

Nde I

Ppu10 I

BfrB I

Nsi I

Xho I

Sci I

EcoR I

GCCGCAGAATTCCATATGCATCTCGAG

387



**A.**



LGGDCC-PQMLRELQETNAALQDVRELLRQQVKEITFLKNTVMECDACG-MQPARTPGTS-

POPOKPPQPPQPKPPQPKPEPE-GTGSSE-KDEL

FIGURE 2C.

Bbr I      EcoP15 I  
Hind III    Nco I      EcoP15 I

AAGCTTACCATGGGAAAGTTCACTGTGGTGGCGGCGGCGTTGCTGCTGCTGGGCGCGGTG 60

M G K F T V V A A A L L L L G A V

BamH I  
Taq II'

CGGGCCGAGGGATCCAGCCTGGGTGGAGACTGTTGTCCACAGATGCTTCGAGAACTCCAG 120

R A E G S S L G G D C C P Q M L R E L Q

EcoICR I  
Sac I  
BspM I      EcoHK I  
BstZ2 I      BstZ2 I

GAGACTAATGCGGCGCTGCAAGACGTGAGAGAGCTCTTGCGACAGCAGGTCAAGGAGATC 180

E T N A A L Q D V R E L L R Q Q V K E I

EcoP15 I      Eco57 I      BsaM I

ACCTTCCTGAAGAATACGGTGATGGAATGTGACGCTTGCGGAATGCAGCCCGCACGCACC 240

T F L K N T V M E C D A C G M Q P A R T

314.8 (sheet 6 of 30)

Spe I

CCCGGTACTAGTCCGCAGCCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAA

300

P G T S P Q P Q P K P Q P Q P Q P Q P K

Acc65 I

Kpn I

Eco52 I

CCGCAGCCGAAACCGGAACCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTG TAG GCG

360

P Q P K P E P E G T G S S E K D E L .

Nde I

Ppu10 I

BfrB I

Nsi I

Xho I

Sci I

EcoR I


GCCGCAGAATTCCATATGCATCTCGAG

387

FIGURE 2D.

Figure 3: MOUSE TSP3 OLIGOMERIZATION DOMAIN KDEL  
RECEPTOR INHIBITOR PROTEIN

A.



B.

Signal cleavage site

MGKFTVVAALLLLGAVRAE-GSS -

LGGDCC-KALVTQLTLFNQILVELRDDIRDQVKEMSLIRN'TIMECQVCG-

PQPQKPQPQPQPQPKPQPKPEPE-GTGSSE-KDEL




FIGURE 3C.

31488 (sheet 9 of 30)

Acc65 I

Kpn I

CCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCGCAGCCGAAACCGGAACCGGAAGGTACC

300

P Q P Q P Q P Q P K P Q P K P E P E G T

Nde I

Ppu10 I

BfrB I

Nsi I

Xho I

Sci I

Eco52 I

EcoR I

GGATCATCAGAAAAAGATGAGTTGTAGGCGGCCGCAGAATTCCATATGCATCTCGAG


357

G S S E K D E L .

FIGURE 3D.

Figure 4: MOUSE TSP3 OLIGOMERIZATION DOMAIN KDEL  
RECEPTOR INHIBITOR PROTEIN

A.



B.

Signal cleavage site



MGKFTVVAALLLLGAVRAE-GSS -

LGGDCC-GEQTKALVTQLTLFNQILVELRDDIRDQVKEMSLIRNTIMECQVCG-

PQPQPKPQPQPQPQPQKPEPE-GTGSSE-KDEL

31.88 (sheet 11 of 30)




FIGURE 4C.



31,88 (sheet 12 of 30)

CCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCGCAGCCGAAACCGGAA 300

P Q P K P Q P Q P Q P Q P K P Q P K P E

Acc65 I Kpn I Eco52 I EcoR I Nde I Ppu10 I BfrB I  
CCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTG TAG GCGGCCGCAGAATTCCATATG 360


P E G T G S S E K D E L .

Nsi I Xho I Sci I  
CATCTCGAG 369

FIGURE 4D.

Figure 5: XENOPUS TSP4 OLIGOMERIZATION DOMAIN KDEL  
RECEPTOR INHIBITOR PROTEIN

A.



B.

Signal cleavage site

MGKFTVAAALLLLGAVRAE-GSS -

LGGDCC-GDVSRQLIGQITQMNQMLGELRDVMRQQVKETMFLRNTIAECQACG-

PQPQPKPQPQPQPQPKPEPE-GTGSSE-KDEL

31488 (sheet 14 of 30)




FIGURE 5C

31488 (sheet 15 of 30)

CCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCGCAGCCGAAACCGGAA

300

P Q P K P Q P Q P Q P Q P K P Q P K P E

Acc65 I

Kpn I

Eco52 I

EcoR I

Nde I

Ppu10 I

BfrB I

CCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTGTAGGCGGCCGCAGAATTCCATATG

360

ATAC

P E G T G S S E K D E L .

Nsi I

Xho I


Sci I

CATCTCGAG

369

FIGURE 5D.

Figure 6: HUMAN COMP OLIGOMERIZATION DOMAIN  
KDEL RECEPTOR INHIBITOR PROTEIN



B.

Signal cleavage site

MRYMILGLLALAAVCSAAKK-GSS -  
LGGDCC-SDLGPQMLRELQETNAALQDVRDWLRQQVREITFLKNTVMECDACG-  
PQPQKPQPQPQPQPKPEPE-GTGSSE-KDEL

31488 (sheet 17 of 30)




FIGURE 6C.

31488 (sheet 18 of 30)

CCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCGCAGCCGAAACCGGAA 300

P Q P K P Q P Q P Q P Q P K P Q P K P E

Acc65 I Kpn I Eco52 I EcoR I Nde I Ppu10 I BfrB I  
CCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTGTAGGCGGCCGCAGAATTCCATATG 360

P E G T G S S E K D E L .

Nsi I Xho I Scl I  
CATCTCGAG 369

FIGURE 6D.





31788 (sheet 20 of 30)




FIGURE 7C.

31488 (sheet 21 of 30)

Acc65 I                      Kpn I                      Eco52 I      EcoRI      Nde I

GAACCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTGTAGGCGGCCGCAGAATTCCAT 300


E P E   G   T   G   S   S   E   K   D   E   L   .

Ppu10 I  
BfrB I  
Nsi I  
Xho I  
Sci I

ATGCATCTCGAG 312

FIGURE 7D.

Figure 8: HUMAN TSP3 OLIGOMERIZATION DOMAIN KDEL  
RECEPTOR INHIBITOR PROTEIN



B.

Signal cleavage site

MRYMILGLLALAAVCSAAKK-GSS-  
LGGDCC-GEQTKALVTQLTFNQILVELRDDIRDQVKEMSLIRNTIMECQVCG-  
PQPQPKPQPQPQPQPQPQKPEPE-GTGSSE-KDEL

31488(sheet 23 of 30)




FIGURE 8C.

31488 (sheet 24 of 30)

CCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCGCAGCCGAAACCGGAA

300

P Q P K P Q P Q P Q P Q P K P Q P K P E

Acc65 I  
Kpn I

Eco52 I

EcoR I

Nde I

Ppu10 I

BfrB I

CCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTGTAGGCGGCCGCAGAATTCCATATG

360

P E G T G S S E K D E L .

Nsi I

Xho I

Sci I

CATCTCGAG

369

FIGURE 8D.

A.



MRYMILGLLALAAVCSAAKK-GSS-

LGGDCC-GDFNRQFLGQMTQLNQLLGEVKDLLRQQVKETSFLRNTIAECQACG-  
PQQPQKPQPQPQPQPKPEPE-GTGSSE-KDEL

91488 (sheet 2 of 30)




FIGURE 9C.

31488 (sheet 27 of 30)

CCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCGCAGCCGAAACCGGAA

300

P Q P K P Q P Q P Q P Q P K P Q P K P E

Acc65 I  
Kpn I

Eco52 I

EcoR I

Nde I

Ppu10 I

BfrB I

CCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTGTAGGCGGCCGCAGAATTCCATATG

360

P E G T G S S E K D E L .

Nsi I

Xho I

Sci I

CATCTCGAG

369

FIGURE 9D.



**A.**



PQ<sup>+</sup>PQPQPQPQPQPKPQPKPEP-GTGSSE-KDEL

31.28 (sheet 29 of 30)




FIGURE 10C.

3 188 (sheet 30 p 30)

EcoP15 I      Eco57 I      BsaM I

TTCCTGAAGAATACGGTGATGGAATGTGACGCTTGCGGAATGCAGCCCGCACGCACCCCC 300

F L K N T V M E C D A C G M Q P A R T P

Spe I

GGTACTAGTCCGCAGCCGCAGCCGAAACCGCAGCCGCAGCCGCAGCCGCAGCCGAAACCG 360

G T S P Q P Q P K P Q P Q P Q P Q P K P

Acc65 I      Kpn I      Eco52 I

AGCCGAAACCGGAACCGGAAGGTACCGGATCATCAGAAAAAGATGAGTTG TAG GCGGCC 420

Q P K P E P E G T G S S E K D E L .

EcoR I      Nde I      Ppu10 I      BfrB I      Nsi I      Xho I      Sci I

GCAGAATTCCATATGCATCTCGAG 444

FIGURE 10D .




FIG. 1A

SIGNAL CLEAVAGE SITE

M G K F T V V A A L L L G A V R A E - G S S -

L G G D L A - P Q M L R E L Q E T N A A L Q D V R E L L R Q Q V K E I T F L K N T V M E C D A C G - M Q P A R T P G T S -

P Q P Q K P Q P Q P Q P K P Q P K P E P E - G T G S S E - K D E L

FIG. 1B




FIG. 1C




FIG. 1D






FIG. 2C







FIG. 2D






FIG. 3C





FIG. 3D



**FIG. 4A**

## SIGNAL CLEAVAGE SITE

MCKFTVAAALLLGAVRAE-GSS-

LGGDCC-GEQTKALVTQLTLFNQILVELRDDIRDQVKEMSLIRNTIMECQVCG-

[illegible]

**FIG. 4B**




FIG. 4C

CCG CAG CCG A A C C G C A G C C G C A G C C G C A G C C G A A C C G C A G C C G G A A C C G G A A 300

P Q P K P Q P Q P Q P Q P Q P Q P K P E

CCG CAG CCG T A C C G G A T C A T C A G A A A A G A T G A G T T G TAG C C G C C G C C G C A G A A T T C C A T A T G 360

Acc65I KpnI

Eco52I EcoRI NdeI Ppu10I BfrBI

P E G T G S S E K D E L .

NsiI XhoI SclI CATCTCGAG 369

FIG. 4D




FIG. 5A

SIGNAL CLEAVAGE SITE

M G K F T V V A A L L L L G A V R A E - G S S -

L G G D C C - G D V S R Q L I G Q I T Q M N Q M L G E L R D V M R Q Q V K E T M F L R N T I A E C Q A C G -

P Q P Q P K P Q P Q P Q P K P Q P K P E P E - G T G S S E - K D E L

FIG. 5B






FIG. 5C

CCGCAGCCGAAACCGCAGCCGCGAGCCGCGAGCCGAAACCGCGAAACCGGAA 300

P Q P K P Q P Q P Q P Q P Q P Q P Q P

---

---

E

Acc65I  
 KpnI  
 Eco52I  
 EcoRI  
 Ppu10I  
 BfrBI  
 NdeI  
 CCGGAAGGTACCGGATCATCAGAAAGATGAGTTGCGCGCCGCAAGATTCCATATG  
 360  
 P E G T C S S E K D E L .  
 :A T A C

**FIG. 5D**




FIG. 6A

SIGNAL CLEAVAGE SITE

M R Y M I L G L L A L A V C S A A K K - G S S -

L G G D C C - S D L G P Q M L R E L Q E T N A A L Q D V R D W L R Q Q V R E I T F L K N T V M E C D A C G -

P Q P Q K P Q P Q P Q P K P Q K P E P E - G T G S S E - K D E L

FIG. 6B




FIG. 6C

CCG CAG CCG A A C C G C A G C C G C A G C C G C A A A C C G C A G C C G A A C C G G A A 300

P Q P K P Q P Q P Q P Q P Q P K P E

+

CCG G A G G T A C C G G A T C A T C A G A A A A G A T G A G T T G T A G C C G C C G C A G A A T T C C A T A T C 360

Acc65I KpnI NdeI Ppu10I BfrBI EcoRI Eco52I

P E G T G S S E K D E L .

NsiI XhoI SclI  
C A T C T C G A C 369

FIG. 6D




FIG. 7A

SIGNAL CLEAVAGE SITE

M R Y M I L G L L A L A A V C S A A K K - G S S -

L G G D C C - Q K L Q N L F I N F C I I L I C L L I C I I V M L L -

P Q Q P K P Q P Q P Q P K P Q P K P E P E - G T G S S E - K D E L

• RESIDUES CRITICAL FOR PENTAMER FORMATION

FIG. 7B

seq. and the amino acid sequence of the protein are shown. The amino acid sequence is shown in the lower part of the figure.




FIG. 7C





FIG. 7D






FIG. 8A

SIGNAL CLEAVAGE SITE

M R Y M I L G L L A L A V C S A A K K - G S S -

L G G D C C - G E Q T K A L V T Q L T L F N Q I L V E L R D D I R D Q V K E M S L I R N T I M E C Q V C G -

P Q P Q K P Q P Q P Q P Q P K P E P E - G T G S S E - K D E L

FIG. 8B




FIG. 8C

FIG. 8D




FIG. 9A

SIGNAL CLEAVAGE SITE

M R Y M I L G L L A L A A V C S A A K K - G S S -

L G G D C C - G D F N R Q F L G Q M T Q L N Q L L G E V K D L L R Q Q V K E T S F L R N T I A E C Q A C G -

P Q P Q K P Q P Q P Q P K P Q P K P E P E - G T G S S E - K D E L

FIG. 9B




FIG. 9C

CCG CAG CCG A A CCG CAG CCG CAG CCG CAG CCG CAG CCG A A CCG CAG CCG A A CCG G A A 300

P Q P K P Q P Q P Q P Q P Q P K P Q P K P E

-----

CCG G A A G G T A C C G G A T C A T C A G A A A A G A T G A G T T G T A G C G C C G C A G A A T T C C A T A T G 360

Acc65I

KpnI

Eco52I

EcoRI

NdeI

Ppu10I

BfrBI

P E G T G S S E K D E L .

NsiI  
XhoI  
SciI  
C A T C T C G A G 369

FIG. 9D







FIG. 10C





**COMBINED DECLARATION  
AND POWER OF ATTORNEY****(Original, Design, National Stage of PCT, Divisional, Continuation or C-I-P Application)**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**KDEL RECEPTOR INHIBITORS**

This declaration is of the following type:

- ☒ original
- ☐ design
- ☐ national stage of PCT.
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (C-I-P)

the specification of which: *(complete (a), (b), or (c))*

- (a) ☐ is attached hereto.
- (b) ☒ was filed on July 29, 1998 as Application Serial No. 09/124,671.
- (c) ☐ was described and claimed in PCT International Application No. filed on and was amended on *(if applicable)*.

**Acknowledgement of Review of Papers and Duty of Candor**

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56.

☐ In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.98.

**Priority Claim**

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed

*(complete (d) or (e))*

- (d) ☒ no such applications have been filed.
- (e) ☐ such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY	APPLICATION NO.	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
			PRIORITY CLAIMED UNDER 35 USC 119 [ ] YES NO [ ]
			[ ] YES NO [ ]
			[ ] YES NO [ ]
ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
			[ ] YES NO [ ]
			[ ] YES NO [ ]
			[ ] YES NO [ ]

### Claim for Benefit of Prior U.S. Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date

### Claim for Benefit of Earlier U.S./PCT Application(s) under 35 U.S.C. 120

*(complete this part only if this is a divisional, continuation or C-I-P application)*

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	---

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	---


### Power of Attorney

As a named inventor, I hereby appoint Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geist, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murnane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Scheinfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439 and Rochelle K. Seide Reg. No. 32,300 of the firm of BAKER & BOTTS, L.L.P., with offices at 30 Rockefeller Plaza, New York, New York 10112, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

SEND CORRESPONDENCE TO: BAKER & BOTTS, L.L.P. 30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112 CUSTOMER NUMBER: 21003	DIRECT TELEPHONE CALLS TO: BAKER & BOTTS, L.L.P. (212) 705-5000
--	---

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section

1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	LAST NAME Rothman	FIRST NAME James	MIDDLE NAME E.
RESIDENCE & CITIZENSHIP	CITY New York	STATE or FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP US
POST OFFICE ADDRESS	POST OFFICE ADDRESS 402 East 64th Street, Apt. 10B	CITY New York	STATE or COUNTRY New York
			ZIP CODE 10021
DATE 10/16/98	SIGNATURE OF INVENTOR 		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	LAST NAME Mayhew	FIRST NAME Mark	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY Tarrytown	STATE or FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP Great Britain
POST OFFICE ADDRESS	POST OFFICE ADDRESS 414 Benedict Avenue, Apt. 3E	CITY Tarrytown	STATE or COUNTRY New York
			ZIP CODE 10591
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	LAST NAME Hoe	FIRST NAME Mee	MIDDLE NAME H.
RESIDENCE & CITIZENSHIP	CITY Irvington	STATE or FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP Malaysia
POST OFFICE ADDRESS	POST OFFICE ADDRESS 10 south Cottenet Street, 2S	CITY Irvington	STATE or COUNTRY New York
			ZIP CODE 10533
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY
			ZIP CODE
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY
			ZIP CODE
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY
			ZIP CODE
DATE	SIGNATURE OF INVENTOR		

FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			

Check proper box(es) for any added page(s) forming a part of this declaration

- ☐ Signature for ninth and subsequent joint inventors. Number of pages added \_\_\_\_\_.
- ☐ Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor.  
Number of pages added \_\_\_\_\_.
- ☐ Signature for inventor who refuses to sign, or cannot be reached, by person authorized under 37 CFR 1.47.  
Number of pages added \_\_\_\_\_.

FILE: C: AS1488 072754.0103  
**COMBINED DECLARATION  
AND POWER OF ATTORNEY**

**(Original, Design, National Stage of PCT, Divisional, Continuation or C-I-P Application)**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**KDEL RECEPTOR INHIBITORS**

This declaration is of the following type:

- ☒ original
- ☐ design
- ☐ national stage of PCT.
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (C-I-P)

the specification of which: *(complete (a), (b), or (c))*

~~(a)~~ ☐ is attached hereto.

~~(b)~~ ☒ was filed on July 29, 1998 as Application Serial No. 09/124,671.

~~(c)~~ ☐ was described and claimed in PCT International Application No. filed on and was amended on *(if applicable)*.

**Acknowledgement of Review of Papers and Duty of Candor**

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56.

☐ In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.98.

**Priority Claim**

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed

*(complete (d) or (e))*

(d) ☒ no such applications have been filed.

(e) ☐ such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY	APPLICATION NO.	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
			PRIORITY CLAIMED UNDER 35 USC 119 <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>

ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>
			<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/>

### Claim for Benefit of Prior U.S. Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date

### Claim for Benefit of Earlier U.S./PCT Application(s) under 35 U.S.C. 120

*(complete this part only if this is a divisional, continuation or C-I-P application)*

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	---

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
--------------------------	---------------	---

### Power of Attorney

As a named inventor, I hereby appoint Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geist, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murnane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Scheinfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439 and Rochelle K. Seide Reg. No. 32,300 of the firm of BAKER & BOTTS, L.L.P., with offices at 30 Rockefeller Plaza, New York, New York 10112, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

SEND CORRESPONDENCE TO:  
 BAKER & BOTTS, L.L.P.  
 30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112  
 CUSTOMER NUMBER: 21003

DIRECT TELEPHONE CALLS TO:  
 BAKER & BOTTS, L.L.P.  
 (212) 705-5000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section

FULL NAME OF SOLE OR FIRST INVENTOR	LAST NAME Rothman	FIRST NAME James	MIDDLE NAME E.
RESIDENCE & CITIZENSHIP	CITY New York	STATE or FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP US
POST OFFICE ADDRESS	POST OFFICE ADDRESS 402 East 64th Street, Apt. 10B	CITY New York	STATE or COUNTRY New York
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	LAST NAME Mayhew	FIRST NAME Mark	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY Tarrytown	STATE or FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP Great Britain
POST OFFICE ADDRESS	POST OFFICE ADDRESS 414 Benedict Avenue, Apt. 3E	CITY Tarrytown	STATE or COUNTRY New York
DATE 6/28/98	SIGNATURE OF INVENTOR <i>Mark Mayhew</i>		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	LAST NAME Hoe	FIRST NAME Mee	MIDDLE NAME H.
RESIDENCE & CITIZENSHIP	CITY Irvington	STATE or FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP Malaysia
POST OFFICE ADDRESS	POST OFFICE ADDRESS 10 south Cottenet Street, 2S	CITY Irvington	STATE or COUNTRY New York
DATE 6/28/98	SIGNATURE OF INVENTOR <i>Mee Hoe</i>		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY
DATE	SIGNATURE OF INVENTOR		



FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			

Check proper box(es) for any added page(s) forming a part of this declaration

- ☐ Signature for ninth and subsequent joint inventors. Number of pages added \_\_\_\_\_.
- ☐ Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor.  
Number of pages added \_\_\_\_\_.
- ☐ Signature for inventor who refuses to sign, or cannot be reached, by person authorized under 37 CFR 1.47.  
Number of pages added \_\_\_\_\_.

# SEQUENCE LISTING

<110> Rothman, James  
Mayhew, Mark  
Hoe, Mee

<120> KDEL RECEPTOR INHIBITORS

<130> 31488

<140> US 09/124,671

<141> 1998-07-29

<160> 42

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 46

<212> PRT

<213> Ratus ratus

<400> 1

Gly	Asp	Leu	Ala	Pro	Gln	Met	Leu	Arg	Glu	Leu	Gln	Glu	Thr	Asn	Ala
1				5					10					15	
Ala	Leu	Gln	Asp	Val	Arg	Glu	Leu	Leu	Arg	Gln	Gln	Val	Lys	Glu	Ile
			20					25					30		
Thr	Phe	Leu	Lys	Asn	Thr	Val	Met	Glu	Cys	Asp	Ala	Cys	Gly		
			35				40					45			

<210> 2

<211> 46

<212> PRT

<213> Homo sapiens

<400> 2

Ser	Asp	Leu	Gly	Pro	Gln	Met	Leu	Arg	Glu	Leu	Gln	Glu	Thr	Asn	Ala
1				5					10					15	
Ala	Leu	Gln	Asp	Val	Arg	Asp	Trp	Leu	Arg	Gln	Gln	Val	Arg	Glu	Ile
			20					25					30		
Thr	Phe	Leu	Lys	Asn	Thr	Val	Met	Glu	Cys	Asp	Ala	Cys	Gly		
			35				40					45			

<210> 3

<211> 46

<212> PRT

<213> Mus musculus

<400> 3

Gly	Glu	Gln	Thr	Lys	Ala	Leu	Val	Thr	Gln	Leu	Thr	Leu	Phe	Asn	Gln
1				5					10					15	

Ile Leu Val Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met  
 20 25 30  
 Ser Leu Ile Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly  
 35 40 45

<210> 4  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Gly Glu Gln Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln  
 1 5 10 15  
 Ile Leu Val Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met  
 20 25 30  
 Ser Leu Ile Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly  
 35 40 45

<210> 5  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens

<400> 5  
 Gly Asp Phe Asn Arg Gln Phe Leu Gly Gln Met Thr Gln Leu Asn Gln  
 1 5 10 15  
 Leu Leu Gly Glu Val Lys Asp Leu Leu Arg Gln Gln Val Lys Glu Thr  
 20 25 30  
 Ser Phe Leu Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly  
 35 40 45

<210> 6  
 <211> 46  
 <212> PRT  
 <213> Xenopus laevis

<400> 6  
 Gly Asp Val Ser Arg Gln Leu Ile Gly Gln Ile Thr Gln Met Asn Gln  
 1 5 10 15  
 Met Leu Gly Glu Leu Arg Asp Val Met Arg Gln Gln Val Lys Glu Thr  
 20 25 30  
 Met Phe Leu Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly  
 35 40 45

<210> 7  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens

<400> 7  
 Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys  
 1 5 10 15  
 Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu

20

25

<210> 8  
<211> 9  
<212> PRT  
<213> papillomavirus

&lt;400&gt; 8

Leu Leu Leu Gly Thr Leu Asn Ile Val  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> papillomavirus

&lt;400&gt; 9

Leu Leu Met Gly Thr Leu Gly Ile Val  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> papillomavirus

&lt;400&gt; 10

Thr Leu Gln Asp Ile Val Leu His Leu  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> papillomavirus

&lt;400&gt; 11

Gly Leu His Cys Tyr Glu Gln Leu Val  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> papillomavirus

&lt;400&gt; 12

Pro Leu Lys Gln His Phe Gln Ile Val  
1 5

<210> 13  
<211> 115  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

<223> chimeric rat comp

<400> 13

```
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1          5          10          15
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Leu Ala Pro Gln Met
 20          25          30
Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp Val Arg Glu
 35          40          45
Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys Asn Thr Val
 50          55          60
Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr Pro Gly Thr
 65          70          75          80
Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro
 85          90          95
Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys
100          105          110
Asp Glu Leu
115
```

<210> 14

<211> 387

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric rat COMP-KDEL

<400> 14

```
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg      60
cgggccgagg gatccagcct ggggtggagac ctagcccccac agatgcttcg agaactccag      120
gagactaatg cggcgctgca agacgtgaga gagctcttgc gacagcaggt caaggagatc      180
accttcctga agaatacggg gatggaatgt gacgcttgcg gaatgcagcc cgcacgcacc      240
cccgtacta gtccgcagcc gcagccgaaa ccgcagccgc agccgcagcc gcagccgaaa      300
ccgcagccga aaccggaacc ggaaggtacc ggatcatcag aaaaagatga gttgtaggcg      360
gccgcagaat tccatatgca tctcgag                                     387
```

<210> 15

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> chimeric rat COMP-KDEL

<400> 15

```
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala
 1          5          10          15
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Pro Gln Met
 20          25          30
Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp Val Arg Glu
 35          40          45
Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys Asn Thr Val
```

50                      55                      60  
 Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr Pro Gly Thr  
 65                      70                      75                      80  
 Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro  
                     85                      90                      95  
 Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys  
                     100                      105                      110  
 Asp Glu Leu  
                     115

<210> 16  
 <211> 387  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric rat COMP-KDEL

<400> 16  
 aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
 cgggccgagg gatccagcct ggggtggagac tgttgtccac agatgcttcg agaactccag 120  
 gagactaatg cggcgctgca agacgtgaga gagctcttgc gacagcaggt caaggagatc 180  
 accttcctga agaatacggg gatggaatgt gacgcttgcg gaatgcagcc cgcacgcacc 240  
 cccggtacta gtccgcagcc gcagccgaaa ccgcagccgc agccgcagcc gcagccgaaa 300  
 ccgcagccga aaccggaacc ggaaggtacc ggatcatcag aaaaagatga gttgtaggcg 360  
 gccgcagaat tccatatgca tctcgag 387

<210> 17  
 <211> 105  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric mouse TSP3-KDEL

<400> 17  
 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
 1                      5                      10                      15  
 Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Lys Ala Leu  
                     20                      25                      30  
 Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val Glu Leu Arg Asp  
                     35                      40                      45  
 Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile Arg Asn Thr Ile  
                     50                      55                      60  
 Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro Lys Pro Gln Pro  
 65                      70                      75                      80  
 Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly  
                     85                      90                      95  
 Thr Gly Ser Ser Glu Lys Asp Glu Leu  
                     100                      105

<210> 18  
 <211> 357

<212> DNA  
<213> Artificial Sequence

<220>  
<223> chimeric mouse TSP3-KDEL

<400> 18  
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
cgggccgagg gatccagcct ggggtggagac tgttgtaagg cattggtcac ccagctcacc 120  
ctcttcaacc agatcctagt ggagcttcgg gacgacatcc gagaccaggt gaaggaaatg 180  
tcactcatcc ggaacaccat catggagtgt caggtgtgcg gtccgcagcc gcagccgaaa 240  
ccgcagccgc agccgcagcc gcagccgaaa ccgcagccga aaccggaacc ggaaggtacc 300  
ggatcatcag aaaaagatga gttgtaggcg gccgcagaat tccatatgca tctcgag 357

<210> 19  
<211> 109  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> chimeric mouse TSP3-KDEL

<400> 19  
Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
1 5 10 15  
Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Glu Gln  
20 25 30  
Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val  
35 40 45  
Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile  
50 55 60  
Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro  
65 70 75 80  
Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
85 90 95  
Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
100 105

<210> 20  
<211> 369  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> chimeric mouse TSP3-KDEL

<400> 20  
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
cgggccgagg gatccagcct ggggtggagac tgttggtggg agcagaccaa ggcattggtc 120  
accagctca ccctcttcaa ccagatccta gtggagcttc gggacgacat ccgagaccag 180  
gtgaaggaaa tgtcactcat ccggaacacc atcatggagt gtcaggtgtg cgggccgcag 240  
ccgcagccga aaccgcagcc gcagccgcag ccgcagccga aaccgcagcc gaaaccggaa 300  
ccggaaggta ccggatcatc agaaaaagat gagttgtagg cggccgcaga attccatatg 360

<210> 21  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric *Xenopus laevis* TSP4-KDEL

<400> 21  
 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
 1 5 10 15  
 Val Arg Ala Glu Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Asp Val  
 20 25 30  
 Ser Arg Gln Leu Ile Gly Gln Ile Thr Gln Met Asn Gln Met Leu Gly  
 35 40 45  
 Glu Leu Arg Asp Val Met Arg Gln Gln Val Lys Glu Thr Met Phe Leu  
 50 55 60  
 Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly Pro Gln Pro Gln Pro  
 65 70 75 80  
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
 85 90 95  
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
 100 105

<210> 22  
 <211> 369  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric *Xenopus laevis* TSP4-KDEL

<400> 22  
 aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
 cgggcccagagg gatccagcct ggggtggagac tgttgtggtg acgtcagcag acagttgatt 120  
 ggccagataa cccaaatgaa tcagatgctg ggagagctcc gagatgtcat gagacagcag 180  
 gtgaaagaga ccatgttctt gagaaacacc attgcagaat gccaggcctg tggcccgcag 240  
 ccgcagccga aaccgcagcc gcagccgcag ccgcagccga aaccgcagcc gaaaccggaa 300  
 ccggaaggta ccggatcatc agaaaaagat gagttgtagg cggccgcaga attccatatg 360  
 catctcgag 369

<210> 23  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human COMP-KDEL

<400> 23  
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser



1	5	10	15
Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Ser Asp Leu			
20	25	30	
Gly Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln			
35	40	45	
Asp Val Arg Asp Trp Leu Arg Gln Gln Val Arg Glu Ile Thr Phe Leu			
50	55	60	
Lys Asn Thr Val Met Glu Cys Asp Ala Cys Gly Pro Gln Pro Gln Pro			
65	70	75	80
Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro			
85	90	95	
Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu			
100	105		

<210> 24  
 <211> 372  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human COMP-KDEL

<400> 24	
aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccggc agtctgcagc	60
gctgccaaaa aaggatccag cctgggtgga gactgttggt cagacctggg cccgcagatg	120
cttcgggaac tgcaggaaac caacgcggcg ctgcaggacg tgcgggactg gctgcggcag	180
caggtcaggg agatcacgtt cctgaaaaac acggtgatgg agtgtgacgc gtgcggggccg	240
cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg	300
gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat	360
atgcatctcg ag	372

<210> 25  
 <211> 90  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human PLB-KDEL

<400> 25		
Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser		
1	15	
Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gln Lys Leu		
20	30	
Gln Asn Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu		
35	45	
Ile Cys Ile Ile Val Met Leu Leu Pro Gln Pro Gln Pro Lys Pro Gln		
50	60	
Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu		
65	75	80
Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu		
85	90	

<210> 26  
 <211> 315  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human PLB-KDEL

<400> 26  
 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccgc agtctgcagc 60  
 gctgccaaaa aaggatccag cctgggtgga gactgttggtc aaaagctaca gaatctattt 120  
 atcaatttct gtctcatctt aatatgtctc ttgtgatctc gtatcatcgt gatgcttctc 180  
 ccgcagccgc agccgaaacc gcagccgcag ccgcagccgc agccgaaacc gcagccgaaa 240  
 ccggaaccgg aaggtagcgg atcatcagaa aaagatgagt tgtaggcggc cgcagaattc 300  
 catatgcata tcgag 315

<210> 27  
 <211> 109  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric human TSP3-KDEL

<400> 27  
 Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser  
 1 5 10 15  
 Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Glu Gln  
 20 25 30  
 Thr Lys Ala Leu Val Thr Gln Leu Thr Leu Phe Asn Gln Ile Leu Val  
 35 40 45  
 Glu Leu Arg Asp Asp Ile Arg Asp Gln Val Lys Glu Met Ser Leu Ile  
 50 55 60  
 Arg Asn Thr Ile Met Glu Cys Gln Val Cys Gly Pro Gln Pro Gln Pro  
 65 70 75 80  
 Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
 85 90 95  
 Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
 100 105

<210> 28  
 <211> 372  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> chimeric human TSP3-KDEL

<400> 28  
 aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccgc agtctgcagc 60  
 gctgccaaaa aaggatccag cctgggtgga gactgttggtg gggagcagac caaggcattg 120  
 gtcaccagc tcacctctt caaccagatc ctagtggagc ttcgggacga catccgagac 180  
 caggtgaagg aaatgtcact catccggaac accatcatgg agtgtcaggt gtgcgggtccg 240

cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg 300  
gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat 360  
atgcatctcg ag 372

<210> 29  
<211> 109  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> chimeric human TSP4-KDEL

<400> 29  
Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser  
1 5 10 15  
Ala Ala Lys Lys Gly Ser Ser Leu Gly Gly Asp Cys Cys Gly Asp Phe  
20 25 30  
Asn Arg Gln Phe Leu Gly Gln Met Thr Gln Leu Asn Gln Leu Leu Gly  
35 40 45  
Glu Val Lys Asp Leu Leu Arg Gln Gln Val Lys Glu Thr Ser Phe Leu  
50 55 60  
Arg Asn Thr Ile Ala Glu Cys Gln Ala Cys Gly Pro Gln Pro Gln Pro  
65 70 75 80  
Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Lys Pro Gln Pro Lys Pro  
85 90 95  
Glu Pro Glu Gly Thr Gly Ser Ser Glu Lys Asp Glu Leu  
100 105

<210> 30  
<211> 372  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> chimeric human TSP4-KDEL

<400> 30  
aagcttacca tgggaaggta catgatttta ggcttgctcg cccttgccgc agtctgcagc 60  
gctgccaaaa aaggatccag cctgggtgga gactgttggt gggactttaa ccggcagttc 120  
ttgggtcaaa tgacacaatt aaaccaactc ctgggagagg tgaaggacct tctgagacag 180  
caggtaagg aaacatcatt ttgcgaaac accatagctg aatgccaggc ttgcggtccg 240  
cagccgcagc cgaaaccgca gccgcagccg cagccgcagc cgaaaccgca gccgaaaccg 300  
gaaccggaag gtaccggatc atcagaaaaa gatgagttgt aggcggccgc agaattccat 360  
atgcatctcg ag 372

<210> 31  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide that binds to erd2 receptor

<400> 31  
 Tyr Thr Ser Glu Lys Asp Glu Leu  
 1 5

<210> 32  
 <211> 8  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> peptide that binds to erd2 receptor

<400> 32  
 Leu Asn Tyr Phe Asp Asp Glu Leu  
 1 5

<210> 33  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> alpha-five integrin binding motif

<400> 33  
 Cys Asp Cys Arg Gly Asp Cys Phe Cys  
 1 5

<210> 34  
 <211> 134  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> KDEL/myc

<400> 34  
 Met Gly Lys Phe Thr Val Val Ala Ala Ala Leu Leu Leu Leu Gly Ala  
 1 5 10 15  
 Val Arg Ala Glu Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
 20 25 30  
 Tyr His Pro Asn Ser Thr Cys Gly Ser Ser Leu Gly Gly Asp Cys Cys  
 35 40 45  
 Pro Gln Met Leu Arg Glu Leu Gln Glu Thr Asn Ala Ala Leu Gln Asp  
 50 55 60  
 Val Arg Glu Leu Leu Arg Gln Gln Val Lys Glu Ile Thr Phe Leu Lys  
 65 70 75 80  
 Asn Thr Val Met Glu Cys Asp Ala Cys Gly Met Gln Pro Ala Arg Thr  
 85 90 95  
 Pro Gly Thr Ser Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln  
 100 105 110  
 Pro Gln Pro Lys Pro Gln Pro Lys Pro Glu Pro Glu Gly Thr Gly Ser  
 115 120 125

Ser Glu Lys Asp Glu Leu  
130

<210> 35  
<211> 444  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> KDEL-myc

<400> 35  
aagcttacca tgggaaagtt cactgtggtg gcggcggcgt tgctgctgct gggcgcggtg 60  
cgggcccagg gatccgaaca aaaacttatt tctgaagaag acttgtagca cccaaactca 120  
acatgccgat ccagcctggg tggagactgt tgtccacaga tgcttcgaga actccaggag 180  
actaatgagg cgctgcaaga cgtgagagag ctcttgcgac agcagggtcaa ggagatcacc 240  
ttcctgaaga atacggtgat ggaatgtgac gcttgccgaa tgcagcccgcc acgcaccccc 300  
ggtactagtc cgcagccgca gccgaaaccg cagccgcagc cgcagccgca gccgaaaccg 360  
cagccgaaac cggaaccgga aggtaccgga tcatcagaaa aagatgagtt gtaggcggcc 420  
gcagaattcc atatgcatct cgag 444

<210> 36  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> human myc tag

<400> 36  
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
1 5 10

<210> 37  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> recognition sequence of KDEL receptor

<400> 37  
Lys Asp Glu Leu  
1

<210> 38  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> binds to KDEL receptor

<223> Xaa= any amino acid

<400> 38

Xaa Asp Glu Leu

1

<210> 39

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> binds to KDEL receptor

<400> 39

Ser Glu Lys Asp Glu Leu

1

5

<210> 40

<211> 4

<212> PRT

<213> Ratus ratus

<400> 40

Gly Asp Leu Ala

1

<210> 41

<211> 4

<212> PRT

<213> Ratus ratus

<220>

<221> VARIANT

<222> (0)...(0)

<400> 41

Gly Asp Cys Cys

1

<210> 42

<211> 4

<212> PRT

<213> Mus musculus

<400> 42

Gly Glu Gln Thr

1